<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7594867</article-id><article-id pub-id-type="pmid">33103497</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1837124</article-id><article-id pub-id-type="publisher-id">1837124</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities</article-title><alt-title alt-title-type="left-running-head">A. M. Shawky et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shawky</surname><given-names>Ahmed M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Ibrahim</surname><given-names>Nashwa A.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Abourehab</surname><given-names>Mohammed A. S.</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Abdalla</surname><given-names>Ashraf N.</given-names></name><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4527-8885</contrib-id><name><surname>Gouda</surname><given-names>Ahmed M.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="aff" rid="AF0005">e</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Science and Technology Unit (STU), Umm Al-Qura University</institution>, <city>Makkah</city>, <country>Saudi Arabia</country></aff><aff id="AF0002"><label>b</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University</institution>, <city>Makkah</city>, <country>Saudi Arabia</country></aff><aff id="AF0003"><label>c</label><institution>Department of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University</institution>, <city>Makkah</city>, <country>Saudi Arabia</country></aff><aff id="AF0004"><label>d</label><institution>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University</institution>, <city>Makkah</city>, <country>Saudi Arabia</country></aff><aff id="AF0005"><label>e</label><institution>Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University</institution>, <city>Beni-Suef</city>, <country>Egypt</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Ahmed M. Gouda <email>ahmed.gouda@pharm.bsu.edu.eg</email>, <email>amsaid@uqu.edu.sa</email><institution>Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University</institution>, <city>Beni-Suef</city><postal-code>62514</postal-code>, <country>Egypt</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>10</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="2">15</fpage><lpage>33</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1837124.pdf"/><abstract><title>Abstract</title><p>In the current study, virtual screening of a small library of 1302 pyrrolizines bearing urea/thiourea moieties was performed. The top-scoring hits were synthesised and evaluated for their cytotoxicity against three cancer (MCF-7, A2780, and HT29) and one normal (MRC-5) cell lines. The results of the MTT assay revealed potent cytotoxic activities for most of the new compounds (IC<sub>50</sub> = 0.16&#x02013;34.13&#x02009;&#x003bc;M). The drug-likeness study revealed that all the new compounds conform to Lipinski&#x02019;s rule. Mechanistic studies of compounds <bold>18&#x02009;b</bold>, <bold>19a</bold>, and <bold>20a</bold> revealed the induction of apoptosis and cell cycle arrest at the G<sub>1</sub> phase in MCF-7 cells. The three compounds also displayed potent inhibitory activity against CDK-2 (IC<sub>50</sub> = 25.53&#x02013;115.30&#x02009;nM). Moreover, the docking study revealed a nice fitting of compound <bold>19a</bold> into the active sites of CDK-2/6/9. These preliminary results suggested that compound <bold>19a</bold> could serve as a promising scaffold in the discovery of new potent anticancer agents.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="IENZ_A_1837124_UF0001_C"/></fig><p><list list-type="bullet"><title>Highlights</title><list-item><p>Virtual screening of 1302 pyrrolizines was done using the pharmacophore model of the multi-CDKI <bold>3</bold>.</p></list-item><list-item><p>The top-scoring hits were synthesised and evaluated for their cytotoxic activities.</p></list-item><list-item><p>Compound <bold>19a</bold> showed potent <italic>in&#x000a0;vitro</italic> cytotoxic activity against CDK-2.</p></list-item><list-item><p>Compound <bold>19a</bold> induced apoptosis and cell cycle arrest at the G<sub>1</sub> phase in MCF-7 cells.</p></list-item><list-item><p>The docking study revealed nice fitting of compound <bold>19a</bold> into CDK-2/6/9 with high binding affinities.</p></list-item></list></p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Pyrrolizine</kwd><kwd>urea derivatives</kwd><kwd>cytotoxicity</kwd><kwd>apoptosis</kwd><kwd>cell cycle</kwd><kwd>CDK-2</kwd></kwd-group><counts><fig-count count="11"/><table-count count="7"/><page-count count="19"/><word-count count="14198"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Targeting the oncogenic protein kinases has emerged as a promising strategy in the development of new anticancer agents in the last three decades<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Currently, more than 40 kinase inhibitors were approved by the FDA for the treatment of different types of cancers<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;5</sup></xref>. Among these inhibitors, the cyclin-dependent kinase inhibitors (CDKIs) attracted much attention which could be due to the important role of CDKs in cell division and differentiation<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. Among the CDK family, CDK-2 plays an important role in the progression of cells from G<sub>1</sub> to S cell cycle phases<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. The overexpression of CDK-2 was also reported in several solid tumours such as breast<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>, colon<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>, and ovarian cancers<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref>. In addition, the increase in CDK-2 expression was also associated with the induction of the radio-resistance in glioblastoma cells<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>, and metastasis in prostate cancer<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>. CDK-2 also has a crucial role in DNA replication and apoptosis in different types of cancer<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>.</p><p>These findings highlighted the importance of CDK-2 as a potential target in cancer chemotherapy. Several small molecule inhibitors of CDK-2 have proved potent anticancer activities<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. However, many of these inhibitors have also displayed pan-CDKs inhibitory activity which could be attributed to the high sequence similarity between different members of the CDK family<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. Some of these inhibitors (roscovitine, dinaciclib, and Ro-3306) have succeeded to reach phase I/II clinical trials<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>.</p><p>Our literature review<xref rid="CIT0016" ref-type="bibr"><sup>16&#x02013;18</sup></xref> revealed several CDKIs bearing similar pharmacophoric groups which include two aryl/heterocyclic rings, two carbonyl groups, and a five-membered pyrazole/imidazole core, <xref ref-type="fig" rid="F0001">Figure 1</xref>. Among these inhibitors, compound <bold>1</bold> exhibited moderate inhibitory activity against CDK-2 with an IC<sub>50</sub> value of 0.324&#x02009;&#x003bc;M<sup>15</sup>. Compound <bold>1</bold> also exhibited inhibitory activity against CDK-1/4. The study of structure&#x02013;activity relationship of compound <bold>1</bold> revealed improvement in CDK-2 inhibitory activity on replacement of the ketone oxygen by sulfur<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Multi-CDK inhibitors <bold>1</bold>&#x02013;<bold>5</bold> bearing similar pharmacophoric features.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0001_C"/></fig><p>Compound <bold>2</bold> was reported among a series of pyrazole derivatives <bold>2&#x02013;4</bold> with CDK-1/2 inhibitory activities<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>. Compound <bold>2</bold> displayed inhibitory activity against CDK-2 with an IC<sub>50</sub> value of 140&#x02009;nM. Substitution on the benzoyl ring in compound <bold>2</bold> with 2,6-difluoro groups afforded compound <bold>3</bold> with a 46-fold increase in CDK-2 inhibitory activity, <xref ref-type="fig" rid="F0001">Figure 1</xref>.</p><p>Moreover, compound <bold>4</bold> (AT7519) was obtained in an attempt to optimise the anticancer activity compound <bold>3</bold>. However, compound <bold>4</bold> exhibited weaker inhibitory activity against CDK-2 (IC<sub>50</sub> = 47&#x02009;nM) compared to the parent compound <bold>3</bold> which indicates that the aromatic 4-fluorophenyl moiety is favoured for CDKs inhibition<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, <xref ref-type="fig" rid="F0001">Figure 1</xref>. Mechanistic study of compound <bold>4</bold> also revealed high inhibitory activity against CDK-9, while weaker activity was observed against CDKs 1, 3, 4, and 6<sup>17</sup>. Moreover, replacement of the 4-piperidinyl ring in compound <bold>4</bold> by the <italic>N</italic>-4-((2-aminophenyl)carbamoyl)benzyl moiety afforded compound <bold>5</bold> with higher inhibitory activities against CDK-1/2<sup>18</sup>.</p><p>In addition, several CDKIs were designed bearing substituted urea moiety<xref rid="CIT0019" ref-type="bibr"><sup>19&#x02013;22</sup></xref>. The importance of this moiety in the formation of hydrogen bonding network with the kinase domain which improves inhibitory activities against CDKs was discussed in several reports<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. Honma et&#x000a0;al. investigated the inhibitory activities of several diaryl urea derivatives against CDK-4<sup>19</sup>. The results revealed higher kinase inhibitory activity for the derivatives with the bulky aryl moiety when substituted with H-bond donner (HB<sub>D</sub>)/acceptor (HB<sub>A</sub>) groups. Among these derivatives, compound <bold>6</bold> with the bulky 7-hydroxynaphthalen-1-yl moiety inhibited CDK-4 with an IC<sub>50</sub> value of 7.6&#x02009;&#x003bc;M, <xref ref-type="fig" rid="F0002">Figure 2</xref>. Compound <bold>7</bold> (CDKi 277, <xref ref-type="fig" rid="F0002">Figure 2</xref>) is also a thiazolyl urea derivative which exhibited potent ATP competitive inhibitory activity against CDKs 1, 2, and 5 with IC<sub>50</sub> values of 8, 4, and 5&#x02009;nM, respectively<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Diary urea derivatives <bold>6</bold>&#x02013;<bold>9</bold> with their inhibitory activities against CDKs.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0002_C"/></fig><p>On the other hand, compound <bold>8</bold> was reported with moderate inhibitory activity against CDK-2 (IC<sub>50</sub> = 14.3&#x02009;&#x003bc;M)<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. However, extending the chemical structure of the diaryl urea <bold>9</bold> with methyl piperazine and aminopyrimidine moieties allowed the new compound to occupy a larger volume of the active site of CDK-2, <xref ref-type="fig" rid="F0002">Figure 2</xref>. Accordingly, compound <bold>9</bold> exhibited higher inhibitory activity against CDK-2 than compound <bold>8</bold><sup>22</sup>.</p><sec id="S0001-S2001" disp-level="2"><label>1.1.</label><title>Rationale and design</title><p>Previously, we reported compound <bold>10</bold> among a series of pyrrolizine-5-carboxamide derivatives with potent cytotoxic activity against MCF-7 cells<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>. Although compound <bold>10</bold> was able to activate caspase 3/7 in MCF-7 cells, but the exact mechanism of action of this compound was not investigated. Recently, we reported different pyrrolizine derivatives with weak to moderate inhibitory activities against 20 oncogenic kinases<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. Among these kinases, CDK-2 was the most affected one by all the tested compounds.</p><p>Based on the above-mentioned data, the current study was performed to optimise the cytotoxic potential, study the structure-activity relationship (SAR), and investigate the mechanism of action of the pyrrolizine-5-carboxamide <bold>10</bold>. In this study, scaffold A (<xref ref-type="fig" rid="F0003">Figure 3</xref>) was designed bearing the pharmacophoric groups of the lead compound <bold>10</bold> and the multi-CDKIs <bold>3</bold><sup>17</sup>. In addition, a small library of 1302 urea/thiourea derivatives was generated through different structural modifications in scaffold A, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Supplementary data (Figures S1&#x02013;S42)</ext-link>.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Rational design of scaffold A and general structure of the compound library.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0003_C"/></fig><p>In the last two decades, more than 500 crystal structure of CDKs were released in the protein data bank<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>. Among these, a large number of CDK-2 crystal structures bound to inhibitors of diverse chemical scaffolds were reported<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>. The use of the <italic>in silico</italic> studies (virtual screening, docking studies and molecular dynamics) in the discovery and identification of new potent CDKs inhibitors was previously discussed in several reports<xref rid="CIT0028" ref-type="bibr"><sup>28&#x02013;30</sup></xref>. Among these techniques, virtual screening was used in several studies to design/identify novel CDK-2 inhibitors<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. Poulsen et&#x000a0;al. reported a nitrogen-linked macrocyclic CDK-2 inhibitor using structure-based design and docking studies<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>.</p><p>Moreover, the pharmacophore-based virtual screening was used widely in different steps of the drug discovery process. This technique depends on the generation of a 3D pharmacophore model based on a set of active ligands, a target&#x02013;ligand complex or the apo target. The generated pharmacophore can then be used in screening virtual libraries of molecules to select/optimise the lead compounds<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. The application of virtual screening was also succeeded in the identification of potent CDK-2 inhibitors of diverse chemical nature<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>.</p><p>In the current work, a pharmacophore-based virtual screening of the compound library was performed using the 3&#x02009;D pharmacophore model of the multi-CDKI <bold>3</bold>. The virtual screening was done using Pharmit (<ext-link ext-link-type="uri" xlink:href="http://pharmit.csb.pitt.edu/">http://pharmit.csb.pitt.edu/</ext-link>)<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>. First, the pdb file of compound <bold>3</bold> (LZ9) bound to CDK-2 (pdb: 2VTP) was selected in the user interface. After loading the protein file, the program identified all the pharmacophoric features in the ligand (LZ9) based on the recorded ligand-protein interactions. This features included the aromatic, hydrophobic, hydrogen bond donor/acceptor, and positively/negatively charged moieties, <xref ref-type="fig" rid="F0004">Figure 4</xref>. In the current study, five of the pharmacophoric features in compound <bold>3</bold> which participate in the interactions with amino acids in the active site of CDK-2 were selected to generate the pharmacophoric model. These features included the aromatic phenyl, pyrazole ring (hydrophobic), and imidazole N<sup>2</sup> (HB<sub>A1</sub>), the anilide NH (HB<sub>D</sub>), and the carbonyl oxygen (HB<sub>A2</sub>), <xref ref-type="fig" rid="F0004">Figure 4</xref>.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Compound <bold>3</bold> (LZ9) bound to CDK-2 (pdb 2VTP); (A) pharmacophoric features of compound <bold>3</bold>; (B) pharmacophoric features selected to generate the 3D pharmacophore model used in the virtual screening.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0004_C"/></fig><p>In the virtual screening, the maximum number of rotatable bonds was set to 9, while the radius of the pharmacophoric feature were set to the default values. Compounds with molecular weights &#x0003e; 500 were excluded to avoid violations from Lipinski&#x02019;s rule. The top-scoring hits were ranked based on RMSD in <xref rid="t0001" ref-type="table">Table 1</xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>The top-scoring hits of the compound library based on RMSD.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Rank</th><th align="center">Hit<sup>a</sup></th><th align="center">RMSD</th><th align="center">Rotatable bond</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="left">Naphthalen-1-yl-ureido</td><td align="char" char=".">0.463</td><td align="char" char=".">8</td></tr><tr><td align="left">2</td><td align="left">Naphthalen-1-yl-ureido</td><td align="char" char=".">0.516</td><td align="char" char=".">8</td></tr><tr><td align="left">3</td><td align="left">3-Fluorophenyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">4</td><td align="left">4-Methoxyphenyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">5</td><td align="left">Cyclohexyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">6</td><td align="left">4-Fluorophenyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">7</td><td align="left">Naphthalen-2-yl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">8</td><td align="left">4-Bromophenyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">9</td><td align="left">Naphthalen-1-yl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">10</td><td align="left">Tert-butyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">11</td><td align="left">Naphthalen-1-yl-thioureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">12</td><td align="left">Cyclopentyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">13</td><td align="left">Cycloheptyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">14</td><td align="left">4-Methoxyphenyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr><tr><td align="left">15</td><td align="left">3-Bromophenyl-ureido</td><td align="char" char=".">0.522</td><td align="char" char=".">9</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><sup>a</sup>Hits named according to their aryl urea/thiourea fragment.</p></fn></table-wrap-foot></table-wrap><p>The results of the virtual screening of the compound library revealed the best score for the naphthalen-1-yl bearing hits (R<sub>1</sub> = H, CH<sub>3</sub>). The top 15-scoring-hits also included the naphthalen-1-yl-thioureido, two 4-methoxyphenyl-ureido and two fluorophenyl-ureido hits with the same RMSD, <xref rid="t0001" ref-type="table">Table 1</xref>.</p><p>Based on the above results, the SAR study of scaffold A was achieved through the following modifications in compound <bold>10</bold> (<xref ref-type="fig" rid="F0005">Figure 5</xref>): (i) replacement of the 4-chlorophenyl moiety by naphthalen-1-yl moiety; (ii) replacement of the urea moiety in the naphthalenyl derivatives by thiourea; (iii) replacement of the chloro group in compound <bold>10</bold> with electron donating (R<sub>2</sub> = 4-OCH<sub>3</sub>) or the electron withdrawing (R<sub>2</sub> = 4-F) groups to study the impact of electronic effect of these substituents on cytotoxicity of the new compounds; (iv) replacement of the 4-chlorophenyl in compound <bold>10</bold> moiety by the aliphatic hexyl group to compare the impact of the aliphatic versus aromatic (phenyl/naphthalenyl) moieties on cytotoxic activity of the new compounds; (v) substitution on ring A with electron donating (R<sub>1</sub> = 4-CH<sub>3</sub>) or with electron withdrawing (R<sub>1</sub> = 4-Cl) to study the impact of these substituents on activity.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Virtual screening and structural modifications of scaffold A.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0005_C"/></fig></sec></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Material and methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p>Chemicals and reagents were purchased from Sigma-Aldrich, Darmstadt, Germany. All solvents were analytical grade and were used without purification. Melting points (m.p.) were determined by IA 9100MK digital melting point apparatus. TLC was used to check the purity of the new compounds. the IR spectra were recorded by BRUKER TENSOR 37 spectrophotometer using KBr disc. The IR spectra were expressed in wavenumber (cm<sup>&#x02212;1</sup>). The <sup>1</sup>H-NMR, <sup>13&#x02009;</sup>C-NMR, and DEPT C<sup>135</sup> spectra were recorded in the Faculty of Pharmacy, Umm Al-Qura University, KSA using BRUKER AVANCE III at 500 and 125&#x02009;MHz, respectively. The <italic>J</italic> constant was given in Hz. Shimadzu GCMS QP5050A spectrometer (EI, 70&#x02009;eV, regional centre for mycology and biotechnology, Al-Azhar University, Cairo, Egypt) was used to perform the mass analyses of the new compounds. The quantitative elemental analyses were done in the microanalytical centre, Cairo University. Compounds <bold>12</bold><xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref>, <bold>14a&#x02013;c</bold><xref rid="CIT0038" ref-type="bibr"><sup>38&#x02013;40</sup></xref>, <bold>15a&#x02013;c</bold><xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref> were prepared according to the previous reports. Copies of spectral data including IR, <sup>1</sup>H-NMR, <sup>13&#x02009;</sup>C-NMR, <sup>13&#x02009;</sup>C-NMR, DEPT C<sup>135</sup>, and mass spectra of the new compounds are provided in supplementary (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Figures S43&#x02013;S137</ext-link>). To facilitate the identification of different protons/carbons and their chemical shifts in each of the new compounds, the numbering of the atoms was illustrated in scaffold A, <xref ref-type="fig" rid="F0005">Figure 5</xref>.</p><sec id="S0002-S2001-S3001" disp-level="3"><label>2.1.1.</label><title>General procedure for the preparation of compounds 16&#x02013;20a&#x02013;c</title><p>A mixture of the staring material (2&#x02009;mmol), appropriate isocyanate/isothiocyanate (2.2&#x02009;mmol), TEA (0.5&#x02009;ml) in DCM (30&#x02009;ml) was stirred at rt for 12&#x02009;h. The solvent was evaporated, and the solid product was dissolved in chloroform-acetone (1:1). The formed precipitate was filtered, washed with acetone, and dried to give white amorphous solid product.</p><sec id="S0002-S2001-S3001-S4001" disp-level="4"><label>2.1.1.1.</label><title>7-Cyano-6-(3-hexylureido)-<italic>N</italic>-phenyl-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (16a)</title><p>The title compound was prepared from the reaction of compound <bold>15a</bold> (0.53&#x02009;g, 2&#x02009;mmol) and hexyl isocyanate (0.28&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>16a</bold> was obtained as white amorphous solid product, m.p. 217&#x02013;19&#x02009;&#x000b0;C, yield 57%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3351 (NHs), 3057 (aromatic C&#x02013;H), 2934, 2872 (aliphatic C&#x02013;H), 2225 (CN), 1708, 1646 (COs), 1599, 1538 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1489, 1379, 1318, 1229 (C&#x02013;N, C&#x02013;O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 0.84 (t, 3H, <italic>J</italic>&#x02009;=&#x02009;5.4&#x02009;Hz, hexyl CH<sub>3</sub>), 1.29&#x02013;1.23 (m, 6H, hexyl CH<sub>2</sub>-3&#x02009;+&#x02009;CH<sub>2</sub>-4&#x02009;+&#x02009;CH<sub>2</sub>-5), 1.44&#x02013;1.40 (m, 2H, hexyl CH<sub>2</sub>-2), 2.47&#x02013;2.42 (m, 2H, pyrrolizine CH<sub>2</sub>-2), 2.97 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, pyrrolizine CH<sub>2</sub>-1), 3.13 (q, 2H, <italic>J</italic>&#x02009;=&#x02009;5.9&#x02009;Hz, hexyl CH<sub>2</sub>-1), 4.27 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.6&#x02009;Hz, pyrrolizine CH<sub>2</sub>-3), 6.77 (s, 1H, N<underline>H</underline>CH<sub>2</sub>-), 7.08 (t, 1H, 6.7&#x02009;Hz, Ph C<underline>H</underline>-4), 7.33 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ph CH-3&#x02009;+&#x02009;CH-5), 7.56 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, Ph CH-2&#x02009;+&#x02009;CH-6), 8.36 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 10.42 (s, 1H, Ph-N<underline>H</underline>CO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 14.4 (CH<sub>3</sub>), 22.5 (hexyl CH<sub>2</sub>-5), 24.9 (pyrrolizine CH<sub>2</sub>-2), 25.6 (pyrrolizine CH<sub>2</sub>-1), 26.4 (hexyl CH<sub>2</sub>-3), 30.2 (hexyl CH<sub>2</sub>-2), 31.5 (hexyl CH<sub>2</sub>-4), 40.1 (hexyl CH<sub>2</sub>-1), 49.7 (pyrrolizine CH<sub>2</sub>-3), 84.3 (pyrrolizine C-7), 115.4 (CN), 119.3 (pyrrolizine C-5), 119.4 (Ph CH-2&#x02009;+&#x02009;CH-6), 124.0 (Ph CH-4), 128.7 (pyrrolizine C-7a), 129.4 (Ph CH-3&#x02009;+&#x02009;CH-5), 139.1 (pyrrolizine C-6), 146.0 (Ph C-1), 157.6 (NH<underline>C</underline>ONH), 157.9 (Ph-NH<underline>C</underline>O). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 14.4 (CH<sub>3</sub>), 22.5 (hexyl CH<sub>2</sub>-5), 24.9 (pyrrolizine CH<sub>2</sub>-2), 25.6 (pyrrolizine CH<sub>2</sub>-1), 26.4 (hexyl CH<sub>2</sub>-3), 30.2 (hexyl CH<sub>2</sub>-2), 31.5 (hexyl CH<sub>2</sub>-4), 40.1 (hexyl CH<sub>2</sub>-1), 49.7 (pyrrolizine CH<sub>2</sub>-3), 119.4 (Ph CH-2&#x02009;+&#x02009;CH-6), 124.0 (Ph CH-4), 129.4 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 395 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 5), 394 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 33), 393 ([M]<sup>+</sup>, 100), 392 ([M-1]<sup>+</sup>, 2), 292 (6), 266 (5), 117 (2), 91 (7), 77 (3). Anal. Calcd. for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub> (393.48): C, 67.15; H, 6.92; N, 17.80. Found: C, 66.81; H, 7.34; N, 17.93.</p></sec><sec id="S0002-S2001-S3001-S4002" disp-level="4"><label>2.1.1.2.</label><title>7-Cyano-6-(3-hexylureido)-<italic>N</italic>-(<italic>p</italic>-tolyl)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (16b)</title><p>The title compound was prepared from the reaction of compound <bold>15b</bold> (0.56&#x02009;g, 2&#x02009;mmol) and hexyl isocyanate (0.28&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>16</bold> was obtained as white amorphous solid product, m.p. 231&#x02013;33&#x02009;&#x000b0;C, yield 51%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3314 (NHs), 2954, 2926, 2857 (aliphatic C&#x02013;H), 2224 (CN), 1708, 1669, 1643 (COs), 1600, 1538 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1433, 1318, 1243 (C&#x02013;N, C&#x02013;O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 0.84 (t, 3H, <italic>J</italic>&#x02009;=&#x02009;5.3&#x02009;Hz, hexyl CH<sub>3</sub>), 1.25&#x02013;1.21 (m, 6H, hexyl CH<sub>2</sub>-3&#x02009;+&#x02009;CH<sub>2</sub>-4&#x02009;+&#x02009;CH<sub>2</sub>-5), 1.47&#x02013;1.38 (m, 2H, hexyl CH<sub>2</sub>-2), 2.26 (s, 3H, tolyl CH<sub>3</sub>), 2.48&#x02013;2.40 (m, 2H, pyrrolizine CH<sub>2</sub>-2), 2.97 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.0&#x02009;Hz, pyrrolizine CH<sub>2</sub>-1), 3.13 (q, 2H, <italic>J</italic>&#x02009;=&#x02009;6.7&#x02009;Hz, hexyl CH<sub>2</sub>-1), 4.26 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, pyrrolizine CH<sub>2</sub>-3), 6.76 (s, 1H, N<underline>H</underline>CH<sub>2</sub>-), 7.13 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, Ph CH-3&#x02009;+&#x02009;CH-5), 7.45 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.0&#x02009;Hz, Ph CH-2&#x02009;+&#x02009;CH-6), 8.34 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 10.32 (s, 1H, Ph-N<underline>H</underline>CO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 14.4 (hexyl CH<sub>3</sub>), 20.9 (tolyl CH<sub>3</sub>), 22.5 (hexyl CH<sub>2</sub>-5), 24.9 (pyrrolizine CH<sub>2</sub>-2), 25.6 (pyrrolizine CH<sub>2</sub>-1), 26.4 (hexyl CH<sub>2</sub>-3), 30.2 (hexyl CH<sub>2</sub>-2), 31.5 (hexyl CH<sub>2</sub>-4), 40.1 (hexyl CH<sub>2</sub>-1), 49.7 (pyrrolizine CH<sub>2</sub>-3), 84.3 (pyrrolizine C-7), 115.4 (CN), 119.4 (Ph CH-2&#x02009;+&#x02009;CH-6), 119.7 (pyrrolizine C-5), 128.5 (pyrrolizine C-7a), 129.7 (Ph CH-3&#x02009;+&#x02009;CH-5), 133.0 (Ph C-1), 136.6 (pyrrolizine C-6), 145.9 (Ph C-4), 157.6 (NH<underline>C</underline>ONH), 157.7 (Ph-NH<underline>C</underline>O). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 14.4 (hexyl CH<sub>3</sub>), 20.9 (tolyl CH<sub>3</sub>), 22.5 (hexyl CH<sub>2</sub>-5), 24.9 (pyrrolizine CH<sub>2</sub>-2), 25.6 (pyrrolizine CH<sub>2</sub>-1), 26.4 (hexyl CH<sub>2</sub>-3), 30.2 (hexyl CH<sub>2</sub>-2), 31.5 (hexyl CH<sub>2</sub>-4), 40.1 (hexyl CH<sub>2</sub>-1), 49.7 (pyrrolizine CH<sub>2</sub>-3), 119.4 (Ph CH-2&#x02009;+&#x02009;CH-6), 129.7 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 409 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 9), 408 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 35), 407 ([M]<sup>+</sup>, 100), 406 ([M-1]<sup>+</sup>, 4), 405 ([M-2]<sup>+</sup>, 1), 395 (2), 368 (3), 306 (25), 280 (3), 276 (3), 173 (3), 117 (12), 106 (3), 104 (12), 91 (9), 77 (25). Anal. Calcd. for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub> (407.51): C, 67.79; H, 7.17; N, 17.19. Found: C, 68.14; H, 6.86; N, 16.86.</p></sec><sec id="S0002-S2001-S3001-S4003" disp-level="4"><label>2.1.1.3.</label><title><italic>N</italic>-(4-Chlorophenyl)-7-cyano-6-(3-hexylureido)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (16c)</title><p>The title compound was prepared from the reaction of compound <bold>15c</bold> (0.60&#x02009;g, 2&#x02009;mmol) and hexyl isocyanate (0.28&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>16c</bold> was obtained as white amorphous solid product, m.p. 240&#x02013;2&#x02009;&#x000b0;C, yield 54%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3265 (NHs), 2954, 2923, 2857 (aliphatic C&#x02013;H), 2222 (CN), 1672, 1641 (COs), 1597, 1567 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1492, 1429, 1315, 1241 (C&#x02013;N, C&#x02013;O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 0.83 (t, 3H, <italic>J</italic>&#x02009;=&#x02009;5.7&#x02009;Hz, hexyl CH<sub>3</sub>), 1.23&#x02013;1.19 (m, 6H, hexyl CH<sub>2</sub>-3&#x02009;+&#x02009;CH<sub>2</sub>-4&#x02009;+&#x02009;CH<sub>2</sub>-5), 1.44&#x02013;1.36 (m, 2H, hexyl CH<sub>2</sub>-2), 2.47&#x02013;2.42 (m, 2H, pyrrolizine CH<sub>2</sub>-2), 2.98 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, pyrrolizine CH<sub>2</sub>-1), 3.12 (q, 2H, <italic>J</italic>&#x02009;=&#x02009;5.9&#x02009;Hz, hexyl CH<sub>2</sub>-1), 4.25 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, pyrrolizine CH<sub>2</sub>-3), 6.77 (s, 1H, N<underline>H</underline>CH<sub>2</sub>-), 7.40 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, Ph CH-3&#x02009;+&#x02009;CH-5), 7.58 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ph CH-2&#x02009;+&#x02009;CH-6), 8.37 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 10.55 (s, 1H, Ph-N<underline>H</underline>CO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 14.4 (hexyl CH<sub>3</sub>), 22.5 (hexyl CH<sub>2</sub>-5), 24.9 (pyrrolizine CH<sub>2</sub>-2), 25.6 (pyrrolizine CH<sub>2</sub>-1), 26.4 (hexyl CH<sub>2</sub>-3), 30.1 (hexyl CH<sub>2</sub>-2), 31.5 (hexyl CH<sub>2</sub>-4), 40.1 (hexyl CH<sub>2</sub>-1), 49.7 (pyrrolizine CH<sub>2</sub>-3), 84.3 (pyrrolizine C-7), 115.3 (CN), 118.9 (Ph C-4), 121.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 127.5 (pyrrolizine C-5), 129.0 (pyrrolizine C-7a), 129.3 (Ph CH-3&#x02009;+&#x02009;CH-5), 138.1 (pyrrolizine C-6), 146.2 (Ph C-1), 157.5 (NH<underline>C</underline>ONH), 158.0 (Ph-NH<underline>C</underline>O). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 14.4 (hexyl CH<sub>3</sub>), 22.5 (hexyl CH<sub>2</sub>-5), 24.9 (pyrrolizine CH<sub>2</sub>-2), 25.6 (pyrrolizine CH<sub>2</sub>-1), 26.4 (hexyl CH<sub>2</sub>-3), 30.2 (hexyl CH<sub>2</sub>-2), 31.5 (hexyl CH<sub>2</sub>-4), 40.1 (hexyl CH<sub>2</sub>-1), 49.7 (pyrrolizine CH<sub>2</sub>-3), 121.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 129.3 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 430 ([M&#x02009;+&#x02009;3]<sup>+</sup>, 9), 429 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 30), 428 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 33), 427 ([M]<sup>+</sup>, 100), 426 ([M-1]<sup>+</sup>, 1), 401 (2), 327 (8), 326 (17), 300 (4), 271 (2), 125 (2), 117 (3), 90 (4), 77 (2). Anal. Calcd. for C<sub>22</sub>H<sub>26</sub>ClN<sub>5</sub>O<sub>2</sub> (427.93): C, 61.75; H, 6.12; N, 16.37. Found: C, 62.08; H, 6.43; N, 16.78.</p></sec><sec id="S0002-S2001-S3001-S4004" disp-level="4"><label>2.1.1.4.</label><title>7-Cyano-6-(3-(4-methoxyphenyl)ureido)-<italic>N</italic>-phenyl-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (17a)</title><p>The title compound was prepared from the reaction of compound <bold>15a</bold> (0.53&#x02009;g, 2&#x02009;mmol) and 4-methoxyphenyl isocyanate (0.33&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>17a</bold> was obtained as white amorphous solid product, m.p. 226&#x02013;8&#x02009;&#x000b0;C, yield 62%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3412, 3309, 3262 (NHs), 2836 (aliphatic C&#x02013;H), 2229 (CN), 1670, 1643 (COs), 1600, 1559 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1445, 1322, 1248 (C&#x02013;N, C&#x02013;O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.48&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.00 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 3.71 (s, 3H, OC<underline>H<sub>3</sub></underline>), 4.29 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 6.86 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, MeO-Ph CH-3&#x02009;+&#x02009;CH-5), 7.08 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;6.7&#x02009;Hz, Ph CH-4), 7.37&#x02013;7.34 (m, 4H, Ph CH-3&#x02009;+&#x02009;CH-5+ MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 7.58 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, Ph CH-2&#x02009;+&#x02009;CH-6), 8.49 (s, 1H, MeO-Ph-N<underline>H</underline>), 9.06 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 9.94 (s, 1H, Ph-N<underline>H</underline>CO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 55.6 (O<underline>C</underline>H<sub>3</sub>), 84.5 (pyrrolizine C-7), 114.4 (MeO-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 118.1 (CN), 119.9 (MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 121.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 124.2 (Ph CH-4), 129.4 (Ph CH-3&#x02009;+&#x02009;CH-5), 132.8 (MeO-Ph C-1), 133.4 (pyrrolizine C-5), 139.0 (pyrrolizine C-7a), 146.3 (pyrrolizine C-6), 153.4 (Ph C-1), 154.5 (NHCONH), 155.3 (MeO-Ph C-4), 158.3 (Ph-NH<underline>C</underline>O). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 55.6 (O<underline>C</underline>H<sub>3</sub>), 114.4 (MeO-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 119.9 (MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 121.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 124.2 (Ph CH-4), 129.4 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 294 ([M-123 (4-methoxyaniline)]<sup>+</sup>, 2), 293 ([M-124]<sup>+</sup>, 6), 266 (1), 264 (2), 200 (6), 173 (7), 145 (3), 123 (17), 122 (5), 121 (3), 117 (29), 108 (41), 91 (29), 77 (28), 65 (100). Anal. Calcd. for C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> (415.44): C, 66.49; H, 5.09; N, 16.86. Found: C, 66.73; H, 4.77; N, 17.11.</p></sec><sec id="S0002-S2001-S3001-S4005" disp-level="4"><label>2.1.1.5.</label><title>7-Cyano-6-(3-(4-methoxyphenyl)ureido)-<italic>N</italic>-(<italic>p</italic>-tolyl)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (17b)</title><p>The title compound was prepared from the reaction of compound <bold>15&#x02009;b</bold> (0.56&#x02009;g, 2&#x02009;mmol) and 4-methoxyphenyl isocyanate (0.33&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>17&#x02009;b</bold> was obtained as white amorphous solid product, m.p. 234&#x02013;6&#x02009;&#x000b0;C, yield 63%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3401, 3275 (NHs), 3000 (aromatic C&#x02013;H), 2954, 2857, 2835 (aliphatic C&#x02013;H), 2222 (CN), 1670, 1644 (COs), 1600, 1563 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1430, 1319, 1247 (C-N, C-O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.26 (s, 3H, CH<sub>3</sub>), 2.48&#x02013;2.43 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.00 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 3.72 (s, 3H, OC<underline>H<sub>3</sub></underline>), 4.29 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.0&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 6.89 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, MeO-Ph CH-3&#x02009;+&#x02009;CH-5), 7.14 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, tolyl CH-3&#x02009;+&#x02009;CH-5), 7.37 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 7.47 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, tolyl CH-2&#x02009;+&#x02009;CH-6), 8.47 (s, 1H, MeO-Ph-N<underline>H</underline>CO), 9.05 (s, 1H, pyrrolizine-NHCO), 9.86 (s, 1H, tolyl-NHCO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 20.9 (CH<sub>3</sub>), 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.6 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 55.6 (O<underline>C</underline>H<sub>3</sub>), 84.5 (pyrrolizine C-7), 114.5 (MeO-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 115.5 (CN), 118.2 (MeO-Ph C-1), 119.9 (MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 121.0 (tolyl CH-2&#x02009;+&#x02009;CH-6), 128.9 (pyrrolizine C-5), 129.7 (tolyl <underline>C</underline>H-3+<underline>C</underline>H-5), 132.8 (pyrrolizine C-7a), 133.2 (tolyl C-1), 136.5 (pyrrolizine C-6), 146.2 (tolyl C-4), 154.5 (NHCONH), 155.3 (MeO-Ph <underline>C</underline>-4), 158.1 (tolyl-NHCO). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 20.9 (CH<sub>3</sub>), 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 55.6 (O<underline>C</underline>H<sub>3</sub>), 114.5 (MeO-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 119.9 (MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 121.0 (tolyl CH-2&#x02009;+&#x02009;CH-6), 129.7 (tolyl <underline>C</underline>H-3+<underline>C</underline>H-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 431 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 3), 429 ([M]<sup>+</sup>, 13), 392 (3), 322 (23), 307 (23), 306 ([M-123 (4-methoxyaniline)]<sup>+</sup>, 23), 305 (41), 304 (9), 280 (7), 278 (37), 266 (5), 250 (8), 200 (7), 172 (10), 132 (13), 123 (2), 108 (8), 92 (17), 77 (46), 65 (100). Anal. Calcd. for C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub> (429.47): C, 67.12; H, 5.40; N, 16.31. Found: C, 66.75; H, 4.89; N, 16.78.</p></sec><sec id="S0002-S2001-S3001-S4006" disp-level="4"><label>2.1.1.6.</label><title><italic>N</italic>-(4-Chlorophenyl)-7-cyano-6-(3-(4-methoxyphenyl)ureido)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (17c)</title><p>The title compound was prepared from the reaction of compound <bold>15c</bold> (0.60&#x02009;g, 2&#x02009;mmol) with 4-methoxyphenyl isocyanate (0.33&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>17c</bold> was obtained as white amorphous solid product, m.p. 245&#x02013;7&#x02009;&#x000b0;C, yield 69%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3294, 3163 (NHs), 3088 (aromatic C&#x02013;H), 2212 (CN), 1663 (COs), 1631, 1605 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1489, 1403, 1322, 1210 (C&#x02013;N, C&#x02013;O), 790 (C&#x02013;Cl). <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 500&#x02009;MHz, ppm) <italic>&#x003b4;</italic>: <italic>&#x003b4;</italic> 2.56&#x02013;2.50 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 2.98 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 3.80 (s, 3H, 4-OC<underline>H<sub>3</sub></underline>), 4.39 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 6.20 (s, 1H, NH), 6.88 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8,9&#x02009;Hz, MeO-Ph CH-3&#x02009;+&#x02009;CH-5), 7.31&#x02013;7.22 (m, 5H, NH, Cl-Ph CH-3&#x02009;+&#x02009;CH-5, MeO-Ph CH-2&#x02009;+&#x02009;CH-6&#x02009;+&#x02009;pyrrolizine-NHCO), 7.53 (d, 2H, <italic>J</italic> -= 8.8&#x02009;Hz, Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 9.62 (s, 1H, Cl-Ph-NH). <sup>13&#x02009;</sup>C-NMR (CDCl<sub>3</sub>, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 55.7 (O<underline>C</underline>H<sub>3</sub>), 84.6 (pyrrolizine C-7), 114.6 (MeO-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 115.6 (CN), 117.0 (MeO-Ph C-1), 120.4 (MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 120.9 (Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 129.1 (4-Cl-Ph C-4), 129.8 (4-Cl-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 131.6 (pyrrolizine C-5), 133.0 (pyrrolizine C-7a), 136.7 (pyrrolizine C-6), 146.6 (4-Cl-Ph), 153.6 (NHCONH), 155.9 (MeO-Ph <underline>C</underline>-4), 159.0 (4-Cl-Ph-NH<underline>C</underline>O). DEPT C<sup>135</sup> (CDCl<sub>3</sub>, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 55.7 (O<underline>C</underline>H<sub>3</sub>), 114.6 (MeO-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 120.4 (MeO-Ph CH-2&#x02009;+&#x02009;CH-6), 120.9 (Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 129.8 (4-Cl-Ph <underline>C</underline>H-3+<underline>C</underline>H-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 451 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 4), 450 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 5), 447 ([M-2]<sup>+</sup>, 2), 445 (4), 434 (5), 406 (3), 395 (8), 368 (10), 352 (6), 301 (6), 273 (44), 272 (100), 271 (14), 248 (3), 134 (6), 123 (62), 122 (7), 108 (78), 95 (17), 91 (4), 77 (20). Anal. Calcd. for C<sub>23</sub>H<sub>20</sub>ClN<sub>5</sub>O<sub>3</sub> (449.89): C, 61.40; H, 4.48; N, 15.57. Found: C, 60.96; H, 4.81; N, 15.78.</p></sec><sec id="S0002-S2001-S3001-S4007" disp-level="4"><label>2.1.1.7.</label><title>7-Cyano-6-(3-(4-fluorophenyl)ureido)-<italic>N</italic>-phenyl-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (18a)</title><p>The title compound was prepared from the reaction of compound <bold>15a</bold> (0.53&#x02009;g, 2&#x02009;mmol) and 4-fluorophenyl isocyanate (0.3&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>18a</bold> was obtained as white amorphous solid product, m.p. 242&#x02013;4&#x02009;&#x000b0;C, yield 65%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3402, 3366, 3336, 3280 (NHs), 3058, 3043 (aromatic C&#x02013;H), 2969, 2895 (aliphatic C&#x02013;H), 2221 (CN), 1655 (COs), 1601, 1549 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1448, 1321, 1249 (C&#x02013;N, C&#x02013;O, C&#x02013;F). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.48&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.01 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.30 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.08 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;6.9&#x02009;Hz, Ph C<underline>H</underline>-4), 7.14 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, F-Ph C<underline>H</underline>-2&#x02009;+&#x02009;C<underline>H</underline>-6), 7.33 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, Ph C<underline>H</underline>-3&#x02009;+&#x02009;C<underline>H</underline>-5), 7.47 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, F-Ph C<underline>H</underline>-3&#x02009;+&#x02009;C<underline>H</underline>-5), 7.59 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ph C<underline>H</underline>-2&#x02009;+&#x02009;C<underline>H</underline>-6), 8.55 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 9.29 (s, 1H, F-Ph-NHCO), 9.84 (s, 1H, Ph-NHCO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.6 (pyrrolizine C-7), 115.4 (CN), 115.8 (d, <italic>J</italic>&#x02009;=&#x02009;22.3&#x02009;Hz, F-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 117.8 (pyrrolizine C-5), 120.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 120.8 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, F-Ph CH-2&#x02009;+&#x02009;CH-6), 124.2 (Ph CH-4), 129.1 (pyrrolizine C-7a), 129.3 (Ph CH-3&#x02009;+&#x02009;CH-5), 136.2 (d, <italic>J</italic>&#x02009;=&#x02009;2.7&#x02009;Hz, F-Ph C-1), 139.0 (Ph CH-1), 146.3 (pyrrolizine C-6), 154.2 (NHCONH), 158.0 (d, <italic>J</italic>&#x02009;=&#x02009;238.4&#x02009;Hz, F-Ph C-4), 158.3 (PhNH<underline>C</underline>O). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 115.8 (d, <italic>J</italic>&#x02009;=&#x02009;22.3&#x02009;Hz, F-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 120.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 120.8 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, F-Ph CH-2&#x02009;+&#x02009;CH-6), 124.2 (Ph CH-4), 129.3 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 402 ([M-1]<sup>+</sup>, 2), 377 (4), 376 (17), 375 (50), 374 (17), 340 (4), 316 (32), 315 (22), 314 (100), 267 (2), 187 (4), 156 (2), 79 (5), 77 (4). Anal. Calcd. for C<sub>22</sub>H<sub>18</sub>FN<sub>5</sub>O<sub>2</sub> (403.41): C, 65.50; H, 4.50; N, 17.36. Found: C, 65.83; H, 4.91; N, 17.62.</p></sec><sec id="S0002-S2001-S3001-S4008" disp-level="4"><label>2.1.1.8.</label><title>7-Cyano-6-(3-(4-fluorophenyl)ureido)-<italic>N</italic>-(<italic>p</italic>-tolyl)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (18b)</title><p>The title compound was prepared from the reaction of compound <bold>15b</bold> (0.56&#x02009;g, 2&#x02009;mmol) with 4-fluorophenyl isocyanate (0.3&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>18b</bold> was obtained as white amorphous solid product, m.p. 247&#x02013;9&#x02009;&#x000b0;C, yield 72%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3405, 3329, 3292 (NHs), 3077, 3037, 3001 (aromatic C-H), 2967, 2919, 2868 (aliphatic C&#x02013;H), 2222 (CN), 1652 (COs), 1600, 1547 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1435, 1320, 1210 (C&#x02013;N, C&#x02013;O, C&#x02013;F). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.26 (s, 3H, CH<sub>3</sub>), 2.48&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.00 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.29 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.15&#x02013;7.12 (m, 4H, tolyl CH-3&#x02009;+&#x02009;CH-5 and F-Ph CH-3&#x02009;+&#x02009;CH-5), 7.48&#x02013;7.46 (m, 4H, tolyl CH-2&#x02009;+&#x02009;CH-6 and F-Ph CH-2&#x02009;+&#x02009;CH-6), 8.57 (s, 1H, F-Ph-NHCO), 9.29 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 9.74 (s, 1H, tolyl-N<underline>H</underline>CO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 20.9 (CH<sub>3</sub>), 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.6 (pyrrolizine C-7), 115.4 (CN), 115.8 (d, <italic>J</italic>&#x02009;=&#x02009;22.3&#x02009;Hz, F-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 118.0 (pyrrolizine C-5), 120.0 (tolyl CH-2&#x02009;+&#x02009;CH-6), 120.8 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, F-Ph CH-2&#x02009;+&#x02009;CH-6), 128.9 (pyrrolizine C-7a), 129.7 (tolyl CH-3&#x02009;+&#x02009;CH-5), 133.2 (tolyl C-1), 136.2 (d, <italic>J</italic>&#x02009;=&#x02009;2.1&#x02009;Hz, F-Ph C-1), 136.4 (pyrrolizine C-6), 146.2 (tolyl C-4), 154.2 (NHCONH), 158.0 (d, <italic>J</italic>&#x02009;=&#x02009;238.9&#x02009;Hz, F-Ph C-4), 158.1 (tolyl-NHCO). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 20.9 (CH<sub>3</sub>), 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 115.8 (d, <italic>J</italic>&#x02009;=&#x02009;22.3&#x02009;Hz, F-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 120.0 (tolyl CH-2&#x02009;+&#x02009;CH-6), 120.7 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, F-Ph CH-2&#x02009;+&#x02009;CH-6), 129.7 (tolyl CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 418 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 2), 417 ([M]<sup>+</sup>, 6), 308 (4), 307 (20), 306 (82), 305 (9), 292 (6), 280 (8), 200 (16), 173 (11), 132 (9), 111 (54), 91 (43), 77 (92), 65 (100). Anal. Calcd. for C<sub>23</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>2</sub> (417.44): C, 66.18; H, 4.83; N, 16.78. Found: C, 65.72; H, 4.43; N, 16.65.</p></sec><sec id="S0002-S2001-S3001-S4009" disp-level="4"><label>2.1.1.9.</label><title><italic>N</italic>-(4-Chlorophenyl)-7-cyano-6-(3-(4-fluorophenyl)ureido)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (18c)</title><p>The title compound was prepared from the reaction of compound <bold>15c</bold> (0.60&#x02009;g, 2&#x02009;mmol) with 4-fluorophenyl isocyanate (0.3&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>18c</bold> was obtained as white amorphous solid product, m.p. 261&#x02013;3&#x02009;&#x000b0;C, yield 75%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3403, 3325, 3278 (NHs), 3062, 3046 (aromatic C&#x02013;H), 2993, 2970 (aliphatic C&#x02013;H), 2224 (CN), 1666 (COs), 1598, 1551 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1431, 1315, 1233 (C&#x02013;N, C&#x02013;O, C&#x02013;F), 774 (C&#x02013;Cl). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.48&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.01 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.7&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.29 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.9&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.13 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, F-Ph CH-3&#x02009;+&#x02009;CH-5), 7.40 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, Cl-Ph CH-3&#x02009;+&#x02009;CH-5), 7.48&#x02013;7.43 (m, 2H, F-Ph CH-2&#x02009;+&#x02009;CH-6), 7.62 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 8.56 (s, 1H, F-PH-N<underline>H</underline>CO), 9.27 (s, 1H, pyrrolizine-N<underline>H</underline>CO), 9.94 (s, 1H, Cl-Ph-N<underline>H</underline>CO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.6 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.5 (pyrrolizine C-7), 115.4 (CN), 115.8 (d, <italic>J</italic>&#x02009;=&#x02009;22.3&#x02009;Hz, F-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 117.3 (Cl-Ph C-4), 120.7 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, F-Ph CH-2&#x02009;+&#x02009;CH-6), 121.7 (Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 127.7 (pyrrolizine C-5), 129.2 (Cl-Ph CH-3&#x02009;+&#x02009;CH-5), 129.5 (pyrrolizine C-7a), 136.2 (d, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, F-Ph C-1), 138.0 (pyrrolizine C-6), 146.5 (Cl-Ph C-1), 153.9 (NHCONH), 158.0 (d, <italic>J</italic>&#x02009;=&#x02009;238.0&#x02009;Hz, F-Ph C-4), 158.4 (Cl-Ph-NHCO). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.6 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 115.8 (d, <italic>J</italic>&#x02009;=&#x02009;22.3&#x02009;Hz, F-Ph <underline>C</underline>H-3+<underline>C</underline>H-5), 120.7 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, F-Ph CH-2&#x02009;+&#x02009;CH-6), 121.7 (Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 129.2 (Cl-Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 438 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 5), 437 ([M]<sup>+</sup>, 15), 436 ([M-1]<sup>+</sup>, 2), 404 (6), 403 (14), 402 (2), 293 (14), 292 (82), 291 (7), 262 (2), 173 (5), 145 (3), 119 (15), 91 (43), 77 (37), 64 (100). Anal. Calcd. for C<sub>22</sub>H<sub>17</sub>ClFN<sub>5</sub>O<sub>2</sub> (437.85): C, 60.35; H, 3.91; N, 15.99. Found: C, 59.92; H, 4.27; N, 16.22.</p></sec><sec id="S0002-S2001-S3001-S4010" disp-level="4"><label>2.1.1.10.</label><title>7-Cyano-6-(3-(naphthalen-1-yl)ureido)-<italic>N</italic>-phenyl-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (19a)</title><p>The title compound was prepared from the reaction of compound <bold>15a</bold> (0.53&#x02009;g, 2&#x02009;mmol) with 1-naphthyl isocyanate (0.37&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>19a</bold> was obtained as white amorphous solid product, m.p. 258&#x02013;61&#x02009;&#x000b0;C, yield 74%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3393, 3262 (NHs), 3047 (aromatic C&#x02013;H), 2987, 2951 (aliphatic C&#x02013;H), 2223 (CN), 1671, 1640 (COs), 1553, 1528 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1444, 1319, 1246 (C&#x02013;N, C&#x02013;O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.48&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.02 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.30 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.08 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, Ph CH-4), 7.32 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, Ph C<underline>H</underline>-3&#x02009;+&#x02009;C<underline>H</underline>-5), 7.53-7.48 (m, 2H, naphthalenyl CH-2&#x02009;+&#x02009;pyrrolizine NH), 7.61 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, Ph CH-2&#x02009;+&#x02009;CH-6), 7.66 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, naphthalenyl CH-3), 7.71 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, naphthalenyl CH-4), 7.87 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, naphthalenyl CH-5), 7.96 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, naphthalenyl CH-6), 8.11 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, naphthalenyl CH-7), 8.26 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, naphthalenyl CH-8), 8.89 (s, 1H, naphthalenyl-NHCO), 9.96 (s, 1H, Ph-NHCO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.5 (pyrrolizine C-7), 117.9 (naphthalenyl CH-2), 118.1 (CN), 120.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 121.9 (naphthalenyl CH-4), 122.3 (naphthalenyl CH-8), 124.1 (naphthalenyl CH-7), 124.5 (naphthalenyl CH-6), 126.3 (naphthalenyl CH-3), 126.5 (Ph CH-4), 127.3 (naphthalenyl C-8a), 128.8 (naphthalenyl CH-5), 129.0 (pyrrolizine C-5), 129.3 (Ph CH-3&#x02009;+&#x02009;CH-5), 134.2 (naphthalenyl C-4a), 134.5 (pyrrolizine C-7a), 134.8 (pyrrolizine C-6), 139.0 (Ph C-1), 146.2 (naphthalenyl C-1), 154.9 (NHCONH), 158.3 (Ph-NHCO). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 117.9 (naphthalenyl CH-2), 120.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 121.9 (naphthalenyl CH-4), 122.3 (naphthalenyl CH-8), 124.1 (naphthalenyl CH-7), 124.5 (naphthalenyl CH-6), 126.3 (naphthalenyl CH-3), 126.5 (Ph CH-4), 128.8 (naphthalenyl CH-5), 129.3 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 436 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 7), 432 ([M-3]<sup>+</sup>, 1), 424 (2), 412 (2), 331 (3), 312 (8), 287 (4), 189 (2), 178 (3), 169 (6), 143 (51), 116 (16), 115 (100), 114 (16), 91 (4), 90 (6), 75 (5). Anal. Calcd. for C<sub>26</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub> (435.48): C, 71.71; H, 4.86; N, 16.08. Found: C, 72.12; H, 4.54; N, 16.25.</p></sec><sec id="S0002-S2001-S3001-S4011" disp-level="4"><label>2.1.1.11.</label><title>7-Cyano-6-(3-(naphthalen-1-yl)ureido)-<italic>N</italic>-(<italic>p</italic>-tolyl)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (19b)</title><p>The title compound was prepared from the reaction of compound <bold>15b</bold> (0.56&#x02009;g, 2&#x02009;mmol) with 1-naphthyl isocyanate (0.37&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>19&#x02009;b</bold> was obtained as white amorphous solid product, m.p. 267&#x02013;9&#x02009;&#x000b0;C, yield 76%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3406, 3281 (NHs), 3050 (aromatic C&#x02013;H), 2919, 2867 (aliphatic C&#x02013;H), 2224 (CN), 1671, 1642 (COs), 1553, 1528 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1433, 1390, 1298 (C&#x02013;N, C&#x02013;O). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.26 (s, 3H, CH<sub>3</sub>), 2.48&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.01 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, pyrrolizine <underline>H<sub>2</sub></underline>-1), 4.29 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.12 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, Ph C<underline>H</underline>-3&#x02009;+&#x02009;C<underline>H</underline>-5), 7.49 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, Ph C<underline>H</underline>-2&#x02009;+&#x02009;C<underline>H</underline>-6), 7.60&#x02013;7.55 (m, 2H, naphthalenyl CH-2&#x02009;+&#x02009;pyrrolizine-NH), 7.66 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, naphthalenyl CH-3), 7.71 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, naphthalenyl CH-4), 7.86 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, naphthalenyl CH-6), 7.96 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, naphthalenyl CH-7), 8.12&#x02013;8.09 (m, naphthalenyl CH-5), 8.26 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, naphthalenyl CH-8), 8.88 (s, 1H, naphthalenyl-NHCO), 9.87 (s, 1H, Ph-NHCO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 20.9 (CH<sub>3</sub>), 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.5 (pyrrolizine C-7), 115.5 (CN), 117.9 (naphthalenyl CH-2), 120.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 121.9 (naphthalenyl CH-4), 123.4 (naphthalenyl CH-8), 124.4 (naphthalenyl CH-7), 126.2 (naphthalenyl C-8a), 126.3 (naphthalenyl CH-6), 126.4 (naphthalenyl CH-3), 128.8 (pyrrolizine C-5), 129.0 (naphthalenyl CH-5), 129.7 (Ph CH-3&#x02009;+&#x02009;CH-5), 133.2 (naphthalenyl C-4a), 134.2 (pyrrolizine C-7a), 134.5 (Ph C-1), 134.8 (pyrrolizine C-6), 136.5 (Ph C-4), 146.1 (naphthalenyl C-1), 155.0 (NHCONH), 158.1 (Ph-NHCO). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 20.9 (CH<sub>3</sub>), 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 117.9 (naphthalenyl CH-2), 120.0 (Ph CH-2&#x02009;+&#x02009;CH-6), 121.9 (naphthalenyl CH-4), 123.4 (naphthalenyl CH-8), 124.4 (naphthalenyl CH-7), 126.3 (naphthalenyl CH-6), 126.4 (naphthalenyl CH-3), 129.0 (naphthalenyl CH-5), 129.7 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 450 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 5), 449 ([M]<sup>+</sup>, 8), 448 ([M-1]<sup>+</sup>, 2), 439 (5), 407 (3), 375 (3), 316 (8), 306 (49), 276 (3), 198 (3), 172 (4), 143 (16), 132 (16), 117 (33), 104 (17), 91 (17), 77 (88), 65 (100). Anal. Calcd. for C<sub>27</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> (449.50): C, 72.14; H, 5.16; N, 15.58. Found: C, 71.72; H, 4.86; N, 16.05.</p></sec><sec id="S0002-S2001-S3001-S4012" disp-level="4"><label>2.1.1.12.</label><title><italic>N</italic>-(4-Chlorophenyl)-7-cyano-6-(3-(naphthalen-1-yl)ureido)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (19c)</title><p>The title compound was prepared from the reaction of compound <bold>15c</bold> (0.6&#x02009;g, 2&#x02009;mmol) with 1-naphthyl isocyanate (0.37&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>19c</bold> was obtained as white amorphous solid product, m.p. 274&#x02013;6&#x02009;&#x000b0;C, yield 72%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3396, 3282 (NHs), 3059, 3008 (aromatic C&#x02013;H), 2225 (CN), 1672, 1641 (COs), 1597, 1556 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1492, 1386, 1245 (C&#x02013;N, C&#x02013;O), 791 (C&#x02013;Cl). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.47&#x02013;2.44 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.02 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.1&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.29 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.38 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, Ph C<underline>H</underline>-3&#x02009;+&#x02009;C<underline>H</underline>-5), 7.55&#x02013;7.47 (m, 3H, naphthalenyl CH-2&#x02009;+&#x02009;CH-3&#x02009;+&#x02009;CH-6), 7.63 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, Ph C<underline>H</underline>-2&#x02009;+&#x02009;C<underline>H</underline>-6), 7.70 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, naphthalenyl CH-4), 7.84 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, naphthalenyl CH-5), 7.96 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, naphthalenyl CH-7), 8.11 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;6.7&#x02009;Hz, naphthalenyl CH-8), 8.89 (s, 1H, pyrrolizine-NHCO), 9.22 (s, 1H, naphthalenyl-NHCO), 10.07 (s, 1H, Ph-NHCO). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.4 (pyrrolizine C-7), 115.5 (CN), 117.6 (naphthalenyl C-8a), 117.9 (naphthalenyl CH-2), 119.4 (naphthalenyl CH-4), 121.6 (Ph CH-2&#x02009;+&#x02009;CH-6), 122.2 (naphthalenyl CH-8), 124.4 (naphthalenyl CH-7), 126.3 (naphthalenyl CH-6), 126.5 (naphthalenyl CH-3), 127.2 (Ph C-4), 127.65 (pyrrolizine C-5), 128.8 (naphthalenyl CH-5), 129.2 (Ph CH-3&#x02009;+&#x02009;CH-5), 129.4 (naphthalenyl C-4a), 134.2 (pyrrolizine C-7a), 134.5 (pyrrolizine C-6), 138.1 (Ph C-1), 146.4 (naphthalenyl C-1), 154.7 (NHCONH), 158.4 (Ph-NHCO). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 117.9 (naphthalenyl CH-2), 119.4 (naphthalenyl CH-4), 121.6 (Ph CH-2&#x02009;+&#x02009;CH-6), 122.2 (naphthalenyl CH-8), 124.4 (naphthalenyl CH-7), 126.3 (naphthalenyl CH-6), 126.5 (naphthalenyl CH-3), 128.8 (naphthalenyl CH-5), 129.2 (Ph CH-3&#x02009;+&#x02009;CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 471 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 1), 469 ([M]<sup>+</sup>, 3), 434 (2), 424 (2), 326 (3), 314 (6), 313 (21), 312 (100), 311 (19), 293 (2), 210 (2), 169 (2), 143 (10), 115 (54), 90 (6), 77 (25). Anal. Calcd. for C<sub>26</sub>H<sub>20</sub>ClN<sub>5</sub>O<sub>2</sub> (469.92): C, 66.45; H, 4.29; N, 14.90. Found: C, 66.12; H, 4.67; N, 15.32.</p></sec><sec id="S0002-S2001-S3001-S4013" disp-level="4"><label>2.1.1.13.</label><title>7-Cyano-6-(3-(naphthalen-1-yl)thioureido)-<italic>N</italic>-phenyl-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (20a)</title><p>The title compound was prepared from the reaction of compound <bold>15a</bold> (0.53&#x02009;g, 2&#x02009;mmol) with 1-naphthyl isothiocyanate (0.41&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>20a</bold> was obtained as white amorphous solid product, m.p. 264&#x02013;6&#x02009;&#x000b0;C, yield 69%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3339, 3168 (NHs), 3054 (aromatic C-H), 2964, 2919 (aliphatic C&#x02013;H), 2229 (CN), 1694 (COs), 1596, 1523 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1488, 1398, 1331, 1216, 1189 (C&#x02013;N, C&#x02013;O, C&#x02009;=&#x02009;S). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.47&#x02013;2.39 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.07 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.21 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.0&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.20 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, naphthalenyl CH), 7.32 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, naphthalenyl CH), 7.41 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, naphthalenyl CH), 7.47 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.30&#x02009;Hz, Ph CH-3&#x02009;+&#x02009;CH-5), 7.63&#x02013;7.52 (m, 6H, 5 aromatics Hs&#x02009;+&#x02009;pyrrolizine-NH), 7.87 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, naphthalenyl H), 7.97 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, aromatic CH), 8.04 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.3&#x02009;Hz, naphthalenyl H), 9.85 (s, 1H, Ph-NH), 13.76 (s, 1H, naphthalenyl-NH). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.8 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.3 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 77.4 (pyrrolizine C-7), 108.1 (CN), 110.4 (naphthalenyl C-8a), 120.4 (naphthalenyl CH-2), 123.7 (Ph CH-2&#x02009;+&#x02009;CH-6), 126.1 (naphthalenyl CH-4), 126.3 (naphthalenyl CH-8), 126.6 (naphthalenyl CH-7), 126.6 (pyrrolizine C-5), 127.4 (naphthalenyl CH-6), 128.6 (Ph CH-3&#x02009;+&#x02009;CH-5), 129.1 (naphthalenyl CH-3), 129.4 (Ph CH-4), 129.6 (naphthalenyl CH-5), 130.7 (naphthalenyl C-4a), 134.4 (pyrrolizine C-7a), 135.8 (pyrrolizine C-6), 139.5 (Ph C-1), 146.8 (naphthalenyl C-1), 159.9 (Ph-NHCO), 175.9 (NHCSNH). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.8 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.3 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 120.4 (naphthalenyl CH-2), 123.7 (Ph CH-2&#x02009;+&#x02009;CH-6), 126.1 (naphthalenyl CH-4), 126.3 (naphthalenyl CH-8), 126.6 (naphthalenyl CH-7), 127.4 (naphthalenyl CH-6), 128.6 (Ph CH-3&#x02009;+&#x02009;CH-5), 129.1 (naphthalenyl CH-3), 129.4 (Ph CH-4), 129.6 (naphthalenyl CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 452 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 1), 436 ([M-15]<sup>+</sup>, 2), 434 (7), 432 (13), 395 (2), 375 (4), 314 (100), 296 (4), 285 (5), 268 (2), 251 (2), 188 (6), 91 (6), 77 (11). Anal. Calcd. for C<sub>26</sub>H<sub>21</sub>N<sub>5</sub>OS (451.54): C, 69.16; H, 4.69; N, 15.51. Found: C, 69.46; H, 4.82; N, 15.21.</p></sec><sec id="S0002-S2001-S3001-S4014" disp-level="4"><label>2.1.1.14.</label><title>7-Cyano-6-(3-(naphthalen-1-yl)thioureido)-<italic>N</italic>-(p-tolyl)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (20b)</title><p>The title compound was prepared from the reaction of compound <bold>15b</bold> (0.56&#x02009;g, 2&#x02009;mmol) with 1-naphthyl isothiocyanate (0.41&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>20&#x02009;b</bold> was obtained as white amorphous solid product, m.p. 279&#x02013;81&#x02009;&#x000b0;C, yield 72%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3379, 3281, 3132 (NHs), 3059 (aromatic C-H), 2929, 2837 (aliphatic C&#x02013;H), 2225 (CN), 1664, (C&#x02009;=&#x02009;O), 1599, 1567, 1539 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1459, 1376, 1237, 1151 (C&#x02013;N, C&#x02013;O, C&#x02009;=&#x02009;S). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.36 (s, 3H, CH<sub>3</sub>), 2.52&#x02013;2.49 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.07 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.21 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.05 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, naphthalenyl CH), 7.26 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, naphthalenyl CH), 7.45 (broad s, 1H, naphthalenyl CH), 7.61&#x02013;7.51 (m, 4H, aromatic Hs), 7.86 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, naphthalenyl CH), 7.96 (d, 2H, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, tolyl CH-2&#x02009;+&#x02009;CH-6), 8.06&#x02013;8.02 (m, 2H, aromatic Hs), 9.83 (s, 1H, pyrrolizine-NH), 10.56 (s, 1H, tolyl-NH), 13.71 (broad s, 1H, naphthalenyl-NH). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 21.3 (CH<sub>3</sub>), 25.1 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 26.2 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 48.8 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 109.1 (pyrrolizine C-7), 110.4 (CN), 118.8 (naphthalenyl CH-2), 123.7 (tolyl CH-2&#x02009;+&#x02009;CH-6), 126.1 (naphthalenyl CH-4), 126.3 (naphthalenyl CH-8), 126.6 (naphthalenyl C-8a), 126.6 (naphthalenyl CH-7), 127.0 (pyrrolizine C-5), 127.3 (naphthalenyl CH-6), 128.6 (tolyl CH-3&#x02009;+&#x02009;CH-5), 129.3 (naphthalenyl CH-3), 129.9 (naphthalenyl CH-5), 130.7 (naphthalenyl C-5a), 131.9 ((pyrrolizine C-7a), 134.4 (tolyl C-1), 135.8 (pyrrolizine C-6), 136.1 (tolyl C-4), 145.6 (naphthalenyl C-1), 158.3 (tolyl-NHCO), 176.0 (NHCSNH). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 21.3 (CH<sub>3</sub>), 25.1 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 26.2 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 48.8 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 118.8 (naphthalenyl CH-2), 123.7 (tolyl CH-2&#x02009;+&#x02009;CH-6), 126.1 (naphthalenyl CH-4), 126.3 (naphthalenyl CH-8), 126.6 (naphthalenyl CH-7), 127.3 (naphthalenyl CH-6), 128.6 (tolyl CH-3&#x02009;+&#x02009;CH-5), 129.3 (naphthalenyl CH-3), 129.9 (naphthalenyl CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 466 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 28), 465 ([M]<sup>+</sup>, 16), 462 ([M-3]<sup>+</sup>, 18), 446 (15), 424 (17), 404 (37), 382 (57), 369 (42), 359 (22), 347 (15), 266 (46), 236 (27), 218 (18), 185 (16), 174 (25), 160 (19), 143 (4), 119 (22), 92 (100), 77 (29). Anal. Calcd. for C<sub>27</sub>H<sub>23</sub>N<sub>5</sub>OS (465.57): C, 69.65; H, 4.98; N, 15.04. Found: C, 69.54; H, 4.72; N, 14.87.</p></sec><sec id="S0002-S2001-S3001-S4015" disp-level="4"><label>2.1.1.15.</label><title><italic>N</italic>-(4-chlorophenyl)-7-cyano-6-(3-(naphthalen-1-yl)thioureido)-2,3-dihydro-1<italic>H</italic>-pyrrolizine-5-carboxamide (20c)</title><p>The title compound was prepared from the reaction of compound <bold>15c</bold> (0.6&#x02009;g, 2&#x02009;mmol) with 1-naphthyl isothiocyanate (0.41&#x02009;g, 2.2&#x02009;mmol) according to the general procedure A. Compound <bold>20c</bold> was obtained as white amorphous solid product, m.p. 287&#x02013;9&#x02009;&#x000b0;C, yield 68%. IR&#x0028b;<sub>max</sub>/cm<sup>&#x02212;1</sup> 3279, 3244, 3179 (NHs), 3053 (aromatic C&#x02013;H), 2929 (aliphatic C&#x02013;H), 2224 (CN), 1662 (C&#x02009;=&#x02009;O), 1600, 1567, 1542 (C&#x02009;=&#x02009;C, C&#x02009;=&#x02009;N), 1491, 1332, 1230, 1149 (C&#x02013;N, C&#x02013;O, C&#x02009;=&#x02009;S), 792 (C&#x02013;Cl). <sup>1</sup>H-NMR (DMSO-<italic>d<sub>6</sub></italic>, 500&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 2.49&#x02013;2.41 (m, 2H, pyrrolizine C<underline>H<sub>2</sub></underline>-2), 3.07 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.1&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-1), 4.31 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, pyrrolizine C<underline>H<sub>2</sub></underline>-3), 7.31&#x02013;7.17 (m, 2H), 7.60&#x02013;7.49 (m, 5H), 7.90 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, naphthalenyl CH-4), 8.00 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.0&#x02009;Hz, naphthalenyl CH-5), 8.05 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, naphthalenyl CH-8), 10.12 (s, 1H, pyrrolizine-NH), 10.69 (s, 1H, Cl-Ph-NH), 11.55 (s, 1H, naphthalenyl-NH). <sup>13&#x02009;</sup>C-NMR (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 24.9 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.6 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.6 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 84.7 (pyrrolizine C-7), 108.7 (CN), 111.0 (naphthalenyl C-8a), 120.4 (Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 123.2 (naphthalenyl CH-2), 125.2 (naphthalenyl CH-4), 126.3 (naphthalenyl CH-8), 126.8 (Cl-Ph C-4), 127.1 (naphthalenyl CH-7), 127.2 (naphthalenyl CH-6), 128.0 (naphthalenyl CH-3), 128.8 (Cl-Ph CH-3&#x02009;+&#x02009;CH-5), 129.3 (naphthalenyl CH-5), 134.4 (pyrrolizine C-5), 134.6 (naphthalenyl C-4a), 135.6 (pyrrolizine C-7a), 136.8 (pyrrolizine C-6), 138.4 (Cl-Ph C-1), 146.0 (naphthalenyl C-1), 158.4 (Cl-Ph-NHCO), 173.4 (NH<underline>C</underline>SNH). DEPT C<sup>135</sup> (DMSO, 125&#x02009;MHz, <italic>&#x003b4;</italic> ppm): <italic>&#x003b4;</italic> 25.0 (pyrrolizine <underline>C</underline>H<sub>2</sub>-2), 25.7 (pyrrolizine <underline>C</underline>H<sub>2</sub>-1), 49.6 (pyrrolizine <underline>C</underline>H<sub>2</sub>-3), 120.4 (Cl-Ph CH-2&#x02009;+&#x02009;CH-6), 123.2 (naphthalenyl CH-2), 125.2 (naphthalenyl CH-4), 126.3 (naphthalenyl CH-8), 127.1 (naphthalenyl CH-7), 127.2 (naphthalenyl CH-6), 128.0 (naphthalenyl CH-3), 128.8 (Cl-Ph CH-3&#x02009;+&#x02009;CH-5), 129.3 (naphthalenyl CH-5). MS (EI): <italic>m</italic>/<italic>z</italic> (%) 487 ([M&#x02009;+&#x02009;2]<sup>+</sup>, 28), 486 ([M&#x02009;+&#x02009;1]<sup>+</sup>, 47), 472 (25), 445 (52), 435 (85), 412 (58), 367 (74), 336 (93), 277 (100), 262 (37), 202 (52), 156 (59), 128 (24), 91 (23), 77 (4). Anal. Calcd. for C<sub>26</sub>H<sub>20</sub>ClN<sub>5</sub>OS (485.99): C, 64.26; H, 4.15; N, 14.41. Found: C, 64.56; H, 4.62; N, 14.12.</p></sec></sec></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Biological evaluation</title><sec id="S0002-S2002-S3001" disp-level="3"><label>2.2.1.</label><title>Cytotoxic activity</title><sec id="S0002-S2002-S3001-S4001" disp-level="4"><label>2.2.1.1.</label><title>Cell culture</title><p>The cancer/normal cell lines used in this study were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The cell culture conditions were the same as in our previous reports<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p></sec><sec id="S0002-S2002-S3001-S4002" disp-level="4"><label>2.2.1.2.</label><title>MTT assay</title><p>MTT assay was used to evaluate the cytotoxicity of the new compounds. The cancer/normal cells were incubated for 72&#x02009;h with the test compounds (dissolved in DMSO). The cytotoxic activities (IC<sub>50</sub> values) of the new compounds were determined according to the previous reports<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>.</p></sec></sec><sec id="S0002-S2002-S3002" disp-level="3"><label>2.2.2.</label><title>Annexin V-FITC/PI staining assay</title><p>The apoptotic effect of compounds <bold>18b, 19a</bold>, and <bold>20a</bold> on MCF-7 cells was evaluated after treatment for 24&#x02009;h at 0, 1, 5, and 10&#x02009;&#x000b5;M. The assay was done using Annexin V-FITC/PI staining assay. Flow cytometry (Bechman Coulter, FC500, Brea, CA) was used differentiate apoptotic/necrotic cells from viable cells<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>.</p></sec><sec id="S0002-S2002-S3003" disp-level="3"><label>2.2.3.</label><title>Cell cycle analysis</title><p>The MCF-7 cells were incubated with compounds <bold>18b, 19a</bold>, and <bold>20a</bold> at 0, 1, 5, and 10&#x02009;&#x000b5;M. After 24&#x02009;h treatment. The PI-stained cells was used to analyse cells using flow cytometer (BC, FC500)<sup>44</sup>.</p></sec><sec id="S0002-S2002-S3004" disp-level="3"><label>2.2.4.</label><title>Cdk-2 inhibition assay</title><p>The CDK-2 inhibitory activities of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> were determined <italic>in&#x000a0;vitro</italic> using ADP-Glo<sup>TM</sup> kinase assay (Promega, Madison, WI). The assay was done according to manufacturer&#x02019;s instructions and as described in the previous report<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref>. The results were represented as IC<sub>50</sub> values, <xref rid="t0004" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Computational studies</title><sec id="S0002-S2003-S3001" disp-level="3"><label>2.3.1.</label><title>Molecular docking studies</title><p>The docking studies were done using AutoDock 4.2<sup>46</sup>. Preparation of ligands, proteins, grid, and docking parameter files was done following our previous reports<xref rid="CIT0047" ref-type="bibr"><sup>47&#x02013;49</sup></xref>. The study was performed according to the previous report<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. Discovery studio visualiser was used to visualise the binding interaction<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>. The pdb files of CDK-2 (pdb: 2VTP)<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, CDCK-6 (pdb: 2EUF)<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref>, and CDK-9 (pdb: 3TNH)<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref> were downloaded from protein data bank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb">http://www.rcsb.org/pdb</ext-link>). The results of the docking study of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> were represented in <xref rid="t0005" ref-type="table">Tables 5</xref> and <xref rid="t0006" ref-type="table">6</xref> and <xref ref-type="fig" rid="F0009 F0010 F0011">Figures 9&#x02013;11</xref>. Moreover, the results of the docking study of the remaining compounds into CDKs are provided in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">supplementary data</ext-link> (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Figures S138&#x02013;S152</ext-link>).</p></sec><sec id="S0002-S2003-S3002" disp-level="3"><label>2.3.2.</label><title>Drug-likeness and ADME studies</title><p>SwissADME webserver (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>)<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref> was used to predict the physicochemical characters related to pharmacokinetic parameters of the new compounds. The study was performed following the previous report<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. The molecular weights, ClogP, number of hydrogen bond donner (HBD), and hydrogen bond acceptor (HBA) of the new compounds were calculated checked for any violation from Lipinski&#x02019;s rule<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>. The chemical structures were sketched and calculation start following submission of the chemical structures. MVs, TPSA, and DLSs were calculated using Molsoft webserver (<ext-link ext-link-type="uri" xlink:href="http://molsoft.com/mprop/">http://molsoft.com/mprop/</ext-link>). The expected GIT absorption percent (<bold>%</bold>Abs) of the new compounds was also calculated according to the previous report<xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref>.</p></sec></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Chemistry</title><p>Preparation of the starting compounds <bold>12</bold><sup>37</sup> and <bold>14a&#x02013;c</bold><xref rid="CIT0038" ref-type="bibr"><sup>38&#x02013;40</sup></xref> was performed according to the previous reports, <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>. Briefly, the lactam derivative <bold>11</bold> was reacted with dimethyl sulphate followed by reaction with malononitrile to give compound <bold>12</bold>. On the other hand, the anilides <bold>14a&#x02013;c</bold> were prepared form the reaction of (un)substituted-anilines with chloroacetyl chloride. The starting materials <bold>15a&#x02013;c</bold> were obtained from the reaction of compound <bold>12</bold> with the acetanilides <bold>14a&#x02013;c</bold> in refluxing acetone<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Reagents and conditions: (a) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, benzene, CH<sub>2</sub>(CN)<sub>2</sub>; (b) ClCH<sub>2</sub>COCl, g. acetic acid, CH<sub>2</sub>COONa; (c) acetone, K<sub>2</sub>CO<sub>3</sub>, reflux, 24&#x02009;h.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_SCH0001_C"/></fig><p>The target urea derivatives <bold>16&#x02013;20a&#x02013;c</bold> (<xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>) were prepared from the reaction of compounds 1<bold>5a&#x02013;c</bold> with the appropriate isocyanate in DCM according to the previous report<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>.</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Reagents and conditions: (d) hexyl isocyanate, TEA, DCM, stir, rt, 12&#x02009;h; (e) appropriate isocyanate, TEA, DCM, stir, rt, 12&#x02009;h; (f) appropriate isocyanate/isothiocyanate, TEA, DCM, stir, rt, 12&#x02009;h.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_SCH0002_C"/></fig><p>The crude white solid product was dissolved in chloroform/acetone and the white amorphous solid formed was collected. The chemical structural of the new compounds was confirmed by spectral and elemental analyses, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Supplementary data (Figures S43&#x02013;S137)</ext-link>.</p></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Biological evaluation</title><sec id="S0003-S2002-S3001" disp-level="3"><label>3.2.1.</label><title>Cytotoxic activity</title><sec id="S0003-S2002-S3001-S4001" disp-level="4"><label>3.2.1.1.</label><title>Evaluation of cytotoxic activity</title><p>All the new compounds were evaluated for their cytotoxicity against three cancer (MCF-7, A2780, and HT29) cell lines. Selection of these cell lines was based on previous findings which reported an overexpression of CDK-2 in breast, ovarian, and colon cancers<xref rid="CIT0008" ref-type="bibr"><sup>8&#x02013;10</sup></xref>.</p><p>The investigation of cytotoxicity of the new compounds was performed using the MTT assay<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>. The results were expressed in IC<sub>50</sub> values (the concentration required to inhibit the growth of cancer cells by 50% compared to the untreated control), <xref rid="t0002" ref-type="table">Table 2</xref>.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Cytotoxic activity of compounds <bold>10</bold>, <bold>16&#x02013;20a&#x02013;c</bold> and lapatinib against MCF-7, A2780, and HT29 cell lines. <inline-graphic xlink:href="IENZ_A_1837124_ILG0001_C.jpg" content-type="color"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="center">Comp. no.</th><th rowspan="2" align="center">R1</th><th rowspan="2" align="center">R2</th><th rowspan="2" align="center">X</th><th colspan="3" align="center">(IC50&#x02009;&#x000b1;&#x02009;SD &#x003bc;M)<sup>a</sup><hr/></th><th rowspan="2" align="center">Average &#x003bc;M</th></tr><tr><th align="center">MCF-7</th><th align="center">A2780</th><th align="center">HT29</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>16a</bold></td><td align="left">H</td><td align="left">-C<sub>6</sub>H<sub>13</sub></td><td align="left">O</td><td align="char" char=".">0.59&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">0.35&#x02009;&#x000b1;&#x02009;0.18</td><td align="char" char=".">0.85&#x02009;&#x000b1;&#x02009;0.07</td><td align="char" char=".">0.60</td></tr><tr><td align="left"><bold>16b</bold></td><td align="left">CH<sub>3</sub></td><td align="left">-C<sub>6</sub>H<sub>13</sub></td><td align="left">O</td><td align="char" char=".">1.17&#x02009;&#x000b1;&#x02009;0.31</td><td align="char" char=".">0.23&#x02009;&#x000b1;&#x02009;0.04</td><td align="char" char=".">1.56&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char=".">0.99</td></tr><tr><td align="left"><bold>16c</bold></td><td align="left">Cl</td><td align="left">-C<sub>6</sub>H<sub>13</sub></td><td align="left">O</td><td align="char" char=".">34.13&#x02009;&#x000b1;&#x02009;4.61</td><td align="char" char=".">0.53&#x02009;&#x000b1;&#x02009;0.10</td><td align="char" char=".">3.10&#x02009;&#x000b1;&#x02009;0.10</td><td align="char" char=".">12.59</td></tr><tr><td align="left"><bold>17a</bold></td><td align="left">H</td><td align="left">4-MeOPh</td><td align="left">O</td><td align="char" char=".">0.90&#x02009;&#x000b1;&#x02009;0.11</td><td align="char" char=".">0.44&#x02009;&#x000b1;&#x02009;0.03</td><td align="char" char=".">5.29&#x02009;&#x000b1;&#x02009;1.51</td><td align="char" char=".">2.21</td></tr><tr><td align="left"><bold>17b</bold></td><td align="left">CH<sub>3</sub></td><td align="left">4-MeOPh</td><td align="left">O</td><td align="char" char=".">2.85&#x02009;&#x000b1;&#x02009;0.31</td><td align="char" char=".">0.42&#x02009;&#x000b1;&#x02009;0.07</td><td align="char" char=".">1.44&#x02009;&#x000b1;&#x02009;0.17</td><td align="char" char=".">1.57</td></tr><tr><td align="left"><bold>17c</bold></td><td align="left">Cl</td><td align="left">4-MeOPh</td><td align="left">O</td><td align="char" char=".">3.36&#x02009;&#x000b1;&#x02009;0.83</td><td align="char" char=".">0.54&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">0.42&#x02009;&#x000b1;&#x02009;0.16</td><td align="char" char=".">1.44</td></tr><tr><td align="left"><bold>18a</bold></td><td align="left">H</td><td align="left">4-F-Ph</td><td align="left">O</td><td align="char" char=".">10.76&#x02009;&#x000b1;&#x02009;0.07</td><td align="char" char=".">10.58&#x02009;&#x000b1;&#x02009;2.83</td><td align="char" char=".">9.13&#x02009;&#x000b1;&#x02009;0.85</td><td align="char" char=".">10.16</td></tr><tr><td align="left"><bold>18b</bold></td><td align="left">CH<sub>3</sub></td><td align="left">4-F-Ph</td><td align="left">O</td><td align="char" char=".">0.19&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">0.97&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char=".">9.71&#x02009;&#x000b1;&#x02009;2.25</td><td align="char" char=".">3.62</td></tr><tr><td align="left"><bold>18c</bold></td><td align="left">Cl</td><td align="left">4-F-Ph</td><td align="left">O</td><td align="char" char=".">0.29&#x02009;&#x000b1;&#x02009;0.19</td><td align="char" char=".">0.21&#x02009;&#x000b1;&#x02009;0.10</td><td align="char" char=".">1.38&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">0.63</td></tr><tr><td align="left"><bold>19a</bold></td><td align="left">H</td><td align="left">1-naphthalenyl</td><td align="left">O</td><td align="char" char=".">0.40&#x02009;&#x000b1;&#x02009;0.42</td><td align="char" char=".">0.32&#x02009;&#x000b1;&#x02009;0.17</td><td align="char" char=".">0.20&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">0.31</td></tr><tr><td align="left"><bold>19b</bold></td><td align="left">CH<sub>3</sub></td><td align="left">1-naphthalenyl</td><td align="left">O</td><td align="char" char=".">0.44&#x02009;&#x000b1;&#x02009;0.09</td><td align="char" char=".">5.39&#x02009;&#x000b1;&#x02009;1.13</td><td align="char" char=".">0.68&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char=".">2.17</td></tr><tr><td align="left"><bold>19c</bold></td><td align="left">Cl</td><td align="left">1-naphthalenyl</td><td align="left">O</td><td align="char" char=".">1.27&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">3.07&#x02009;&#x000b1;&#x02009;1.50</td><td align="char" char=".">2.56&#x02009;&#x000b1;&#x02009;0.70</td><td align="char" char=".">2.30</td></tr><tr><td align="left"><bold>20a</bold></td><td align="left">H</td><td align="left">1-naphthalenyl</td><td align="left">S</td><td align="char" char=".">0.42&#x02009;&#x000b1;&#x02009;0.15</td><td align="char" char=".">0.16&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">0.72&#x02009;&#x000b1;&#x02009;0.12</td><td align="char" char=".">0.43</td></tr><tr><td align="left"><bold>20b</bold></td><td align="left">CH<sub>3</sub></td><td align="left">1-naphthalenyl</td><td align="left">S</td><td align="char" char=".">4.97&#x02009;&#x000b1;&#x02009;0.42</td><td align="char" char=".">2.04&#x02009;&#x000b1;&#x02009;0.95</td><td align="char" char=".">3.83&#x02009;&#x000b1;&#x02009;0.58</td><td align="char" char=".">3.61</td></tr><tr><td align="left"><bold>20c</bold></td><td align="left">Cl</td><td align="left">1-naphthalenyl</td><td align="left">S</td><td align="char" char=".">1.76&#x02009;&#x000b1;&#x02009;0.95</td><td align="char" char=".">2.81&#x02009;&#x000b1;&#x02009;0.98</td><td align="char" char=".">3.67&#x02009;&#x000b1;&#x02009;1.65</td><td align="char" char=".">2.75</td></tr><tr><td align="left"><bold>10</bold></td><td align="left">3,5-diMe<sup>c</sup></td><td align="left">4-Cl-Ph</td><td align="left">O</td><td align="char" char=".">1.12&#x02009;&#x000b1;&#x02009;0.10</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>Lap.</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="char" char=".">6.77&#x02009;&#x000b1;&#x02009;1.16</td><td align="char" char=".">10.52&#x02009;&#x000b1;&#x02009;0.76</td><td align="char" char=".">12.46&#x02009;&#x000b1;&#x02009;1.27</td><td align="char" char=".">9.92</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p><sup>a</sup>IC<sub>50</sub> is the concentration of test compounds which reduce cellular growth to 50% after treatment for 72&#x02009;h.</p></fn><fn id="TF3"><p><sup>b</sup>Results represent mean IC<sub>50</sub> value&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic>&#x02009;=&#x02009;3); Lap, lapatinib.</p></fn><fn id="TF4"><p><sup>c</sup>CI<sub>50</sub> value quoted from our previous publication<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>.</p></fn></table-wrap-foot></table-wrap><p>The results revealed the ability of the new compounds to inhibit the growth of the selected cancer cell lines with IC<sub>50</sub> values in the range of 0.16&#x02013;34.13&#x02009;&#x003bc;M. Among these derivatives, compound <bold>18b</bold> was the most active against MCF-7 cells (IC<sub>50</sub> = 0.19&#x02009;&#x003bc;M), while compounds <bold>19a</bold> and <bold>20a</bold> were the most potent in inhibiting the growth of HT29 and A2780 cell line, respectively.</p><p>The hexyl urea derivatives <bold>16a&#x02013;c</bold> displayed weak to potent cytotoxic activity against the three cell lines (IC<sub>50</sub> = 0.23&#x02013;34.13&#x02009;&#x003bc;M). Among the three derivatives, compound <bold>16b</bold> was the most active against A2780, while compound <bold>16a</bold> showed the highest cytotoxic activity against MCF-7 and HT29 cell lines, <xref rid="t0002" ref-type="table">Table 2</xref>.</p><p>Furthermore, the 4-methoxyphenyl-urea derivatives <bold>17a&#x02013;c</bold> showed potent cytotoxic activity against the three cancer cell lines with IC<sub>50</sub> values in the range of 0.42&#x02013;5.29&#x02009;&#x003bc;M. Compound <bold>17c</bold> was more active against MCF-7 and HT29 cell lines compared to its hexyl urea <bold>16c</bold>. However, compounds <bold>17a</bold>,<bold>b</bold> were less active against MCF-7 and A2780 cell lines than their hexyl analogs <bold>16a</bold>,<bold>b</bold>, <xref rid="t0002" ref-type="table">Table 2</xref>.</p><p>The 4-fluorophenyl urea derivatives <bold>18a&#x02013;c</bold> showed moderate to potent cytotoxic activities against the three cancer cell lines (IC<sub>50</sub> = 0.19&#x02013;10.76&#x02009;&#x003bc;M). Among these derivatives compound <bold>18b</bold> was the most active against MCF-7 cells. Moreover, compound <bold>18c</bold> exhibited higher cytotoxic activities towards MCF-7 and A2780 cell lines compared to the hexyl <bold>16c</bold> and methoxyphenyl <bold>17c</bold> analogues, <xref rid="t0002" ref-type="table">Table 2</xref>.</p><p>The naphthalenyl urea derivatives <bold>19a&#x02013;c</bold> exhibited the highest cytotoxicity with IC<sub>50</sub> in the range of 0.20&#x02013;5.39&#x02009;&#x003bc;M. Among these derivatives, compound <bold>19a</bold> displayed the highest cytotoxic activity against HT29 cell line. On the other hand, the thiourea derivatives <bold>20a&#x02013;c</bold> exhibited higher cytotoxic activities against A2780 cells than their urea analogues <bold>19a&#x02013;c</bold>. However, they (<bold>20a&#x02013;c</bold>) were less active against MCF-7 and HT29 cells compared to compounds <bold>19a&#x02013;c</bold>, <xref rid="t0002" ref-type="table">Table 2</xref>.</p><p>In conclusion, the results of MTT assay of most of the new compounds revealed higher cytotoxicity compared to lapatinib (IC<sub>50</sub> = 6.77&#x02013;12.46&#x02009;&#x003bc;M). In addition, most of the new compounds (<bold>16a</bold>, <bold>17a</bold>, <bold>18b</bold>,<bold>c</bold>, <bold>19a&#x02013;c</bold>) exhibited higher cytotoxic activities against MCF-7 than the parent compound <bold>10</bold>, <xref rid="t0002" ref-type="table">Table 2</xref>.</p></sec><sec id="S0003-S2002-S3001-S4002" disp-level="4"><label>3.2.1.2.</label><title>Evaluation of cytotoxic selectivity</title><p>Beside the cytotoxic activity, toxicity and selectivity towards normal cells are also critical factors in the discovery of new anticancer agents<xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>. Accordingly, cytotoxicity of the new reported compounds (<bold>16</bold>&#x02013;<bold>20</bold>) was also evaluated in the current study using the normal human foetal lung fibroblast (MRC-5). The investigation was performed using the MTT assay according to the previous reports<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. The results were presented in <xref rid="t0003" ref-type="table">Table 3</xref>.</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Cytotoxicity of compounds <bold>16&#x02013;20a&#x02013;c</bold>, and lapatinib against normal MRC-5 cells and their selectivity indices (SIs).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Comp. no.</th><th rowspan="2" align="center">IC<sub>50</sub> (&#x000b5;M&#x02009;&#x000b1;&#x02009;SD)<sup>a</sup> MRC-5</th><th colspan="3" align="center">Selectivity index<sup>b</sup><hr/></th></tr><tr><th align="center">MCF-7</th><th align="center">A2780</th><th align="center">HT29</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>16a</bold></td><td align="left">11.86&#x02009;&#x000b1;&#x02009;0.87</td><td align="left">20.10</td><td align="left">33.89</td><td align="char" char=".">13.95</td></tr><tr><td align="left"><bold>16b</bold></td><td align="left">2.65&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">2.26</td><td align="left">11.52</td><td align="char" char=".">1.70</td></tr><tr><td align="left"><bold>16c</bold></td><td align="left">0.75&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">0.02</td><td align="left">1.42</td><td align="char" char=".">0.24</td></tr><tr><td align="left"><bold>17a</bold></td><td align="left">2.30&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">2.56</td><td align="left">5.23</td><td align="char" char=".">0.43</td></tr><tr><td align="left"><bold>17b</bold></td><td align="left">6.20&#x02009;&#x000b1;&#x02009;0.88</td><td align="left">2.18</td><td align="left">14.76</td><td align="char" char=".">4.31</td></tr><tr><td align="left"><bold>17c</bold></td><td align="left">3.80&#x02009;&#x000b1;&#x02009;0.25</td><td align="left">1.13</td><td align="left">7.04</td><td align="char" char=".">9.05</td></tr><tr><td align="left"><bold>18a</bold></td><td align="left">10.70&#x02009;&#x000b1;&#x02009;0.61</td><td align="left">0.99</td><td align="left">1.01</td><td align="char" char=".">1.17</td></tr><tr><td align="left"><bold>18b</bold></td><td align="left">1.46&#x02009;&#x000b1;&#x02009;0.42</td><td align="left">7.68</td><td align="left">1.51</td><td align="char" char=".">0.15</td></tr><tr><td align="left"><bold>18c</bold></td><td align="left">0.10&#x02009;&#x000b1;&#x02009;0.01</td><td align="left">0.34</td><td align="left">0.48</td><td align="char" char=".">0.07</td></tr><tr><td align="left"><bold>19a</bold></td><td align="left">2.67&#x02009;&#x000b1;&#x02009;0.37</td><td align="left">6.68</td><td align="left">8.34</td><td align="char" char=".">13.35</td></tr><tr><td align="left"><bold>19b</bold></td><td align="left">1.54&#x02009;&#x000b1;&#x02009;0.20</td><td align="left">3.50</td><td align="left">0.29</td><td align="char" char=".">2.26</td></tr><tr><td align="left"><bold>19c</bold></td><td align="left">2.68&#x02009;&#x000b1;&#x02009;0.37</td><td align="left">2.11</td><td align="left">0.87</td><td align="char" char=".">1.05</td></tr><tr><td align="left"><bold>20a</bold></td><td align="left">0.43&#x02009;&#x000b1;&#x02009;0.13</td><td align="left">1.02</td><td align="left">2.69</td><td align="char" char=".">0.60</td></tr><tr><td align="left"><bold>20b</bold></td><td align="left">2.00&#x02009;&#x000b1;&#x02009;0.75</td><td align="left">0.40</td><td align="left">0.98</td><td align="char" char=".">0.52</td></tr><tr><td align="left"><bold>20c</bold></td><td align="left">2.92&#x02009;&#x000b1;&#x02009;0.60</td><td align="left">1.66</td><td align="left">1.04</td><td align="char" char=".">0.80</td></tr><tr><td align="left"><bold>Lapatinib</bold></td><td align="left">6.74&#x02009;&#x000b1;&#x02009;1.22</td><td align="left">1.00</td><td align="left">0.64</td><td align="char" char=".">0.54</td></tr></tbody></table><table-wrap-foot><fn id="TF5"><p><sup>a</sup>IC<sub>50</sub> against MRC-5 cells after 72&#x02009;h treatment with the test compound, results represent mean IC<sub>50</sub> &#x000b1; SD (<italic>n</italic>&#x02009;=&#x02009;3).</p></fn><fn id="TF6"><p><sup>b</sup>Selectively index (SI) = IC<sub>50</sub> value against normal MRC-5 cells/IC<sub>50</sub> value against cancer cell line.</p></fn></table-wrap-foot></table-wrap><p>The results revealed IC<sub>50</sub> values in the range of 0.10&#x02013;11.86&#x02009;&#x000b5;M. To evaluate the cytotoxic selectivity of the new compounds, the selectivity index (SI) for each compound was calculated. The SI was obtained by dividing its IC<sub>50</sub> value of the compound against normal MRC-5 cells by its IC<sub>50</sub> value against the corresponding cancer cell line, <xref rid="t0003" ref-type="table">Table 3</xref>.</p><p>Among the new compounds, the hexyl urea derivatives <bold>16a&#x02013;c</bold> inhibited the growth of MRC-5 cells with IC<sub>50</sub> values in the range of 0.75&#x02013;11.86&#x02009;&#x000b5;M. among these derivatives, compound <bold>16a</bold> showed the highest selectivity towards the three cell lines with SIs in the range of 13.95&#x02013;33.89.</p><p>Moreover, the 4-methoxyphenyl urea derivatives <bold>17a&#x02013;c</bold> exhibited higher selectivity (SI = 5.23&#x02013;14.76) towards the ovarian cancer cell line (A2780) compared to their 4-fluorophenyl analogues <bold>18a&#x02013;c</bold>. However, compound <bold>18b</bold> displayed more than seven times higher selectivity towards the cancerous MCF-7 cells compared to lapatinib. In addition, the naphthalenyl urea derivatives <bold>19a</bold>&#x02013;<bold>c</bold> displayed higher selectivity towards MCF-7 and HT29 cells compared to their thiourea derivatives <bold>20a</bold>&#x02013;<bold>c</bold>, <xref rid="t0003" ref-type="table">Table 3</xref>.</p></sec><sec id="S0003-S2002-S3001-S4003" disp-level="4"><label>3.2.1.3.</label><title>Structure&#x02013;activity relationship (SAR)</title><p>The relationship between the chemical structure of the new compounds and their cytotoxic activity/selectivity was presented in <xref ref-type="fig" rid="F0006">Figure 6</xref>. Compound <bold>16a</bold> which exhibited potent submicromolar cytotoxicity (IC<sub>50</sub> = 0.35&#x02013;0.85&#x02009;&#x003bc;M) and was the most selective towards three cancer cell lines.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>SAR of cytotoxicity and selectivity of the new compounds against MCF-7, A2780, and HT29 cells.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0006_C"/></fig><p>Substitution on the phenyl ring in compound <bold>16a</bold> with 4-CH<sub>3</sub> increased the cytotoxic activity against A2780 cells. On the other hand, significant decreases in cytotoxic activities of compound <bold>16a</bold> against both MCF-7 and HT29 cell lines were observed on substitution with either 4-CH<sub>3</sub>/Cl groups on the phenyl ring. Moreover, substitution with CH<sub>3</sub>/Cl groups at the <italic>para</italic>-position of the phenyl ring in compound <bold>16a</bold> was associated with decrease in selectivity towards the three cancer cell lines, <xref ref-type="fig" rid="F0006">Figure 6</xref>.</p><p>Replacement of the hexyl group in compound <bold>16a</bold> by 4-methoxyphenyl afforded compound <bold>17a</bold> with slight decrease in cytotoxicity against both MCF-7 and A2780 cells, while significant reduction in activity against HT29 cells was observed. Substitution on the phenyl ring (A) in compound <bold>17a</bold> with 4-CH<sub>3</sub>/Cl resulted in increase in cytotoxic activity against HT29 cells, while cytotoxicity against MCF-7 was decreases, <xref ref-type="fig" rid="F0006">Figure 6</xref>.</p><p>In addition, replacement of the OCH<sub>3</sub> group in compound <bold>17a</bold> by F afforded compound <bold>18a</bold> with sharp decrease in cytotoxicity against the three cancer cell lines. On the other hand, substitution on the phenyl ring of compound <bold>18a</bold> with either the electron donating 4-CH<sub>3</sub> or the electron withdrawing 4-Cl groups improved cytotoxicity against both MCF-7 and A2780 cell lines, <xref ref-type="fig" rid="F0006">Figure 6</xref>.</p><p>Replacement of the hexyl group in compound <bold>16a</bold> by 1-naphthalenyl group afforded compound <bold>19a</bold> which was more active as cytotoxic agent against the three cancer cell lines. Although cytotoxicity of compound <bold>19a</bold> was decreased on substitution with 4-CH<sub>3</sub>/Cl groups on ring A, but the produced derivatives <bold>19b</bold>,<bold>c</bold> were more active than their hexyl analogues <bold>16b</bold>,<bold>c</bold> against MCF-7 and HT29 cells, <xref ref-type="fig" rid="F0006">Figure 6</xref>.</p><p>Replacement of urea oxygen in compound <bold>19a</bold> by sulphur yielded compound <bold>20a</bold> with higher cytotoxicity against A2780 cells but lower cytotoxic activities towards HT29 cells. Substitution on ring A of compound <bold>20a</bold> with the 4-CH<sub>3</sub>/Cl groups resulted in weaker cytotoxic activities against the three cancer cell lines, <xref ref-type="fig" rid="F0006">Figure 6</xref>.</p></sec></sec><sec id="S0003-S2002-S3002" disp-level="3"><label>3.2.2.</label><title>Annexin V-FITC/PI apoptosis assay</title><p>Previously, compound <bold>10</bold>, the lead compound in this study was reported to induce apoptosis in MCF-7 cells through activation of caspase 3/7<sup>23</sup>. Accordingly, the ability of the new compounds to induce apoptosis in the same cells (MCF-7) was investigated in the current study. Compounds <bold>18&#x02009;b</bold>, <bold>19a</bold>, and <bold>20a</bold> the most active against MCF-7 cells were selected for this study. The ability of these compounds to induce apoptosis was evaluated using annexin V fluorescein isothiocyanate (FITC)/Propidium Iodide (PI) staining assay according to the previous report<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>. MCF-7 cells were treated with each the test compounds for 24&#x02009;h. The results were presented in <xref ref-type="fig" rid="F0007">Figure 7</xref>.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Annexin V phases of MCF-7 treated with compound <bold>18b, 19a</bold>, and <bold>20a</bold> at 0, 1, 5, and 10&#x02009;&#x000b5;M (24&#x02009;h, <italic>x</italic>-axis: Annexin V; <italic>y</italic>-axis: PI). C1: necrotic cells; C2: late apoptosis; C3: live cells; C4: early apoptosis. Data shown is mean % cell number&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic>&#x02009;=&#x02009;3). Experiment was repeated x3 times.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0007_C"/></fig><p>The results revealed a significant dose dependent increase of the apoptotic events by compound <bold>18&#x02009;b</bold> from 0% in the control, to 20%, 23%, and 37% at 1, 5, and 10&#x02009;&#x000b5;M, respectively. Similarly, compound <bold>20a</bold> caused increase of 38%, 39%, and 47% at 1, 5, and 10&#x02009;&#x000b5;M, respectively. in addition, compound <bold>19a</bold> caused the highest increase in apoptotic events with 68%, 88%, and 90% at 1, 5, and 10&#x02009;&#x000b5;M, respectively, <xref ref-type="fig" rid="F0007">Figure 7</xref>.</p></sec><sec id="S0003-S2002-S3003" disp-level="3"><label>3.2.4.</label><title>Cell-cycle analysis</title><p>The effect of compounds <bold>18&#x02009;b</bold>, <bold>19a</bold>, and <bold>20a</bold>, on cell-cycle perturbation in MCF-7 cells was investigated based on previous report<xref rid="CIT0044" ref-type="bibr"><sup>44</sup></xref>. The MCF-7 cells were treated with each of the three compounds at 0, 1, 5, and 10&#x02009;&#x000b5;M for 24&#x02009;h. Following this treatment, the propidium iodide (PI)-stained cells were analysed. The results are outlined in <xref ref-type="fig" rid="F0008">Figure 8</xref>.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Flow cytometry bar chart showing the effect of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> at 0, 1, 5, and 10&#x02009;&#x003bc;M on cell cycle distribution of MCF-7 cells after treatment for 24&#x02009;h, values represent the mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic>&#x02009;=&#x02009;3), experiment was repeated &#x000d7;3.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0008_C"/></fig><p>The results of the cell cycle analysis revealed G<sub>1</sub> -S cell cycle arrest by the three compounds (<bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold>). Compound <bold>19a</bold> caused the highest increase in the number of cells in the G<sub>1</sub> cell-cycle phase (70%) at the expense of the other phases, compared to <bold>18b</bold> (53%) and <bold>20a</bold> (57%), in <xref ref-type="fig" rid="F0008">Figure 8</xref>. These results agree with previous reports which indicate that CDK-2 inhibitors arrest cell cycle at the G<sub>1</sub> phase<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>.</p></sec><sec id="S0003-S2002-S3004" disp-level="3"><label>3.2.4.</label><title>Cdk-2 inhibitory activity</title><p>Targeting CDKs is one of the promising strategies in cancer chemotherapy<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. The success of this strategy was confirmed by many CDK inhibitors which reached phase I/II clinical trials as potential anticancer agents<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. Previously, several compounds with pyrrolizine-5-carboxamide scaffold exhibited weak to moderate inhibitory activity against CDK-2<sup>24,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p><p>In the current study, compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold>, the most active in cytotoxic assay (<xref rid="t0002" ref-type="table">Table 2</xref>) were selected to evaluate for their inhibitory activity against CDK-2 <italic>in&#x000a0;vitro</italic>. The assay was performed using Adenosine diphosphate (ADP)-Glo<sup>TM</sup> kinase assay kit (Promega, Madison, WI) following the previous report<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref>. Briefly, the ability of CDK-2 to convert ATP to ADP was used as a measure of the kinase activity. The inhibition in activity of the kinase was determined after treatment with the test compounds relative to the control (DMSO, 5%). Staurosporine was used as positive control. The results of this assay are presented as IC<sub>50</sub> in <xref rid="t0004" ref-type="table">Table 4</xref>.</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Inhibition of CDK-2 by compounds <bold>18b</bold>, <bold>19a,</bold> and <bold>20a</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Comp. no.</th><th align="center">IC<sub>50</sub> (nM)<sup>a</sup> &#x000b1;SEM</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>18b</bold></td><td align="left">115.3&#x02009;&#x000b1;&#x02009;3.20</td></tr><tr><td align="left"><bold>19a</bold></td><td align="left">25.53&#x02009;&#x000b1;&#x02009;1.7</td></tr><tr><td align="left"><bold>20a</bold></td><td align="left">77.90&#x02009;&#x000b1;&#x02009;2.2</td></tr><tr><td align="left"><bold>Staurosporine</bold></td><td align="left">26.39&#x02009;&#x000b1;&#x02009;0.9</td></tr></tbody></table><table-wrap-foot><fn id="TF7"><p>IC<sub>50</sub>, concentration which decrease kinase activity to 50%.</p></fn><fn id="TF8"><p><sup>a</sup>Average of three determinations;.</p></fn></table-wrap-foot></table-wrap><p>The results revealed high <italic>in&#x000a0;vitro</italic> inhibitory activity against CDK-2 by the tested compounds with IC<sub>50</sub> in the nanomolar range. Compound <bold>19a</bold> exhibited the highest inhibitory activity against CDK-2, which was comparable to that of the positive control (staurosporine). The inhibitory activity of compound <bold>19a</bold> was nearly three-fold higher than its thiourea analogue <bold>20a</bold>. Moreover, the inhibitory activities of the two naphthalenyl derivatives <bold>19a</bold> and <bold>20a</bold> against CDK-2 was higher than that of the 4-methoxyphenyl urea <bold>18b</bold>, <xref rid="t0004" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="S0003-S2003" disp-level="2"><label>3.3.</label><title>Computational studies</title><sec id="S0003-S2003-S3001" disp-level="3"><label>3.3.1.</label><title>Molecular docking studies</title><p>To identify the potential mechanism of action and understand the results of the CDK-2 inhibitory assay (<xref rid="t0004" ref-type="table">Table 4</xref>), a molecular docking study was performed into the active site of CDK-2 protein. The study was performed to evaluate the binding free energies (affinities) and inhibition constants of the new compounds into CDK-2. The crystal structure of CDK-2 protein (pdb: 2VTP)<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref> was obtained from protein data bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/3TNW">https://www.rcsb.org/structure/3TNW</ext-link>). AutoDock 4.2 was used to carry out the docking study<xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref>. The docking procedures were performed according to the previous report<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. The grid and docking parameter files were prepared according to the previous reports<xref rid="CIT0047" ref-type="bibr"><sup>47&#x02013;49</sup></xref>. Visualisation of the binding interactions of the new compounds in the active sites of CDK-2 was performed by Discovery studio visualizer<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>.</p><sec id="S0003-S2003-S3001-S4001" disp-level="4"><label>3.3.1.1.</label><title>Docking study into CDK-2</title><p>Initially, the validation of the docking procedures into the active site of CDK-2 was performed. The native ligand, compound <bold>3</bold> (LZ9) was re-docked into the active site of CDK-2. The results revealed superposition of the re-docked ligand <bold>3</bold> over the position of the co-crystallized ligand with RMSD of 0.75&#x02009;&#x000c5; (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Supplementary data, Figure S138</ext-link>). The results of the docking study of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> revealed nice fitting into CDK-2 with binding free energy in the range of &#x02212;9.16 to &#x02212;9.77&#x02009;kcal/mol. The binding affinities of the three compounds towards CDK-2 was also higher than that of the native ligand LZ9, <xref rid="t0005" ref-type="table">Table 5</xref>. The results of the docking study of the remaining derivatives are provided in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">supplementary data (Table S1 and Figures S139&#x02013;S150</ext-link>).</p><p>Among the three derivatives, compound <bold>19a</bold> showed higher binding affinity towards CDK-2 compared to compounds <bold>18b</bold> and <bold>20a</bold> which was matched with their inhibitory activities against CDK-2, <xref rid="t0005" ref-type="table">Table 5</xref>. In addition, the thiourea <bold>20a</bold> exhibited also higher affinity to CDK-2 compared to the 4-flourophenyl derivative <bold>18b</bold> which was also matched with their IC<sub>50</sub> values towards CDK-2, <xref rid="t0004" ref-type="table">Table 4</xref>. To explain these results, the binding modes, orientations, and interactions of the three compounds (<bold>18b, 18a</bold>, and, <bold>20a</bold>) were investigated in comparison to the native ligand to understand their inhibitory activities against CDK-2.</p><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Docking results of compounds <bold>18b</bold>, <bold>19a</bold>, <bold>20a</bold> and LZ9 into CDK-2 (pdb: 2VTP)</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Ligand</th><th rowspan="2" align="center"><italic toggle="yes">&#x00394;</italic>G<italic toggle="yes"><sub>b</sub></italic><sup>a</sup></th><th rowspan="2" align="center"><italic toggle="yes">K<sub>i</sub></italic><sup>b</sup></th><th rowspan="2" align="center">HBs<sup>c</sup></th><th colspan="2" align="center">Atoms in H-bonding<hr/></th><th rowspan="2" align="center">Length <sup>d</sup>(&#x000c5;)</th></tr><tr><th align="center">In ligand</th><th align="center">In protein</th></tr></thead><tbody valign="top"><tr><td rowspan="3"><bold>18&#x02009;b</bold></td><td rowspan="3" align="char" char=".">&#x02212;9.16</td><td rowspan="3" align="char" char=".">193.5&#x02009;nM</td><td rowspan="3" align="char" char=".">3</td><td align="left">Urea N<underline>H</underline></td><td align="left">CO of Leu83</td><td align="char" char=".">1.88</td></tr><tr><td align="left">C<underline>N</underline></td><td align="left">NH of Leu83</td><td align="char" char=".">2.09</td></tr><tr><td align="left">Ph-NH</td><td align="left">CO of Gln131</td><td align="char" char=".">2.06</td></tr><tr><td rowspan="3"><bold>19a</bold></td><td rowspan="3" align="char" char=".">&#x02212;9.97</td><td rowspan="3" align="char" char=".">49.38&#x02009;nM</td><td rowspan="3" align="char" char=".">3</td><td align="left">C<underline>N</underline></td><td align="left">NH of Leu83</td><td align="char" char=".">1.97</td></tr><tr><td align="left">Urea N<underline>H</underline></td><td align="left">CO of Leu83</td><td align="char" char=".">1.80</td></tr><tr><td align="left">Ph-NH</td><td align="left">CO of Gln131</td><td align="char" char=".">2.93</td></tr><tr><td rowspan="4"><bold>20a</bold></td><td rowspan="4" align="char" char=".">&#x02212;9.54</td><td rowspan="4" align="char" char=".">101.28&#x02009;nM</td><td rowspan="4" align="char" char=".">4</td><td align="left">C<underline>N</underline></td><td align="left">NH of Leu83</td><td align="char" char=".">1.90</td></tr><tr><td align="left">Thiourea S</td><td align="left">CO of Asp86</td><td align="char" char=".">2.07</td></tr><tr><td align="left">Thiourea S</td><td align="left">CO of Gln131</td><td align="char" char=".">2.60</td></tr><tr><td align="left">Ph-NH</td><td align="left">CO of Gln131</td><td align="char" char=".">2.76</td></tr><tr><td rowspan="3"><bold>LZ9</bold></td><td rowspan="3" align="char" char=".">&#x02212;7.56</td><td rowspan="3" align="char" char=".">2.81&#x02009;&#x003bc;M</td><td rowspan="3" align="char" char=".">3</td><td align="left">Pyrazole-C<underline>O</underline></td><td align="left">NH of Glu81</td><td align="char" char=".">2.21</td></tr><tr><td align="left">pyrazole NH</td><td align="left">CO of Leu83</td><td align="char" char=".">2.05</td></tr><tr><td align="left">pyrazole NH<bold><italic toggle="yes"><sup>e</sup></italic></bold></td><td align="left">CH of Phe82</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TF9"><p><sup>a</sup>Binding free energy (kcal/mol).</p></fn><fn id="TF10"><p><sup>b</sup>Inhibition constant (n/&#x003bc;M).</p></fn><fn id="TF11"><p><sup>c</sup>HBs, number of hydrogen bonds.</p></fn><fn id="TF12"><p><sup>d</sup>Length in angstrom (&#x000c5;).</p></fn><fn id="TF13"><p><sup>e</sup>Carbon hydrogen bond.</p></fn></table-wrap-foot></table-wrap><p>Investigation of the binding mode of the best fit conformation of compound <bold>19a</bold> revealed partial superposition of the pyrrole ring over the pyrazole ring in compound <bold>3</bold>. Moreover, the naphthalenyl moiety in compound <bold>19a</bold> superposed over the 4-fluorophenyl moiety of compound <bold>3</bold>, <xref ref-type="fig" rid="F0009">Figure 9</xref>.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>Binding mode and interactions of compound <bold>19a</bold> into CDK-2 (pdb: 2VTP)): (A) 3D binding mode of compound <bold>19a</bold> into the active site of CDK-2, the native ligand LZ9 shown as yellow sticks, receptor shown as hydrogen-bond surface; (B) 2D binding mode of compound <bold>19a</bold> into CDK-2 showing three conventional hydrogen bonds, one pi-cation, and several hydrophobic interactions, hydrogen atoms were omitted for clarity.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0009_C"/></fig><p>Compound <bold>19a</bold> exhibited three conventional hydrogen bonds with Leu83 (2 HBs) and Gln131 with bond length in the range of 1.80&#x02013;2.93&#x02009;&#x000c5;, <xref rid="t0005" ref-type="table">Table 5</xref>. The pyrrolidine ring in compound <bold>19a</bold> also formed one carbon hydrogen bond with Asp145. Compound <bold>19a</bold> also showed one pi-anion interaction with Asp145 and a cluster of hydrophobic interactions with Val18, Ala31, Val64, Phe80, Leu134, and Ala144, <xref ref-type="fig" rid="F0009">Figure 9</xref>. These binding mode and interactions of compound <bold>19a</bold> with CDK-2 could account for its high inhibitory activity against CDK-2.</p><p>Compound <bold>20a</bold> also adopted binding orientations in which the naphthalenyl-thiourea side chain superpose the position of 4-fluorophenyl-carboxamide moiety in compound <bold>3</bold>, <xref ref-type="fig" rid="F0010">Figure 10</xref>. Moreover, the phenyl-carboxamide side chain in compound <bold>20a</bold> adopted an orientation superposing over the position of the difluorophenyl-carboxamide chain in LZ9, while the pyrrole ring in compound <bold>20a</bold> overlaid partially over the pyrazole ring in LZ9.</p><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p>Binding modes and interactions of compounds <bold>18b/20a</bold> into CDK-2 (pdb: 2VTP)): A) 3&#x02009;D binding mode of compound <bold>18b</bold> into CDK-2, the native ligand LZ9 shown as yellow sticks, receptor shown as hydrogen-bond surface; B) 3&#x02009;D binding mode of compound <bold>20a</bold> into CDK-2, the native ligand LZ9 shown as yellow sticks; C) 2&#x02009;D binding mode of compound <bold>18b</bold> into CDK-2 showing three conventional hydrogen bonds and several hydrophobic interactions; (C) 2D binding mode of compound <bold>20a</bold> into CDK-2 showing four conventional hydrogen bonds and one pi-anion, and several hydrophobic interactions, hydrogen atoms were omitted for clarity.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0010_C"/></fig><p>The binding interactions of compound <bold>20a</bold> with CDK-2 included four conventional hydrogen bonds with Leu83, Asp86, and Gln131 (2 HBs) amino acids. In addition, one pi-anion and several hydrophobic interactions were also formed between compound <bold>20a</bold> and amino acids in the active site of CDK-2, <xref ref-type="fig" rid="F0010">Figure 10</xref>.</p><p>Although compound <bold>20a</bold> showed higher number of hydrogen bonds with CDK-2, but it exhibited lower affinity than compound <bold>19a</bold> towards CDK-2. This could be attributed to the stronger (shorter) hydrogen bonds formed by compound <bold>19a</bold> with CDK-2 compared to compound <bold>20a</bold>, <xref rid="t0005" ref-type="table">Table 5</xref>.</p><p>On the other hand, compound <bold>18b</bold> exhibited three conventional hydrogen bonds with Leu83 and Gln131 and one carbon hydrogen bond with Asp145. Several hydrophobic interactions of the alkyl and pi-alkyl types were also observed between compound <bold>18b</bold> and amino acids in the active site of CDK-2, <xref ref-type="fig" rid="F0010">Figure 10</xref>.</p><p>The bulkier size of compounds <bold>19a</bold> and <bold>20a</bold> compared to compound <bold>18b</bold> could account even partially to their higher affinities and higher inhibitory activities towards CDK-2. In addition, the higher binding affinities of compounds <bold>19a</bold> and <bold>20a</bold> compared to compound <bold>18b</bold> could be due to higher number and/or stronger hydrogen bonding interactions compared to compound <bold>18b</bold>. Moreover, each of the two compounds (<bold>19a</bold> and <bold>20a</bold>) exhibited one electrostatic interaction of pi-anion type which was absent with compound <bold>18b</bold>. these findings could account even partially for the higher inhibitory activity of compounds <bold>19a</bold> and <bold>20a</bold> compared to compound <bold>18b</bold>.</p><p>Moreover, the results of the docking study into CDK-2 indicated the important role of the urea/thiourea moieties in the formation of hydrogen bonding interactions between the tested pyrrolizines (<bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold>) and amino acids in the active site of CDK-2. In addition, the pyrrolidine ring in the three compounds also contributed hydrophobically in the binding interactions into CDK-2 through the formation of a cluster of hydrophobic interactions with Ala31, Phe80, Leu134, and Ala144.</p><p>However, compounds <bold>18b</bold>, <bold>19a</bold> and <bold>20a</bold> were designed based on the chemical structure of the multi-CDKI <bold>3</bold>. Accordingly, a molecular docking study was performed to investigate other potential targets which could mediate their cytotoxic activities.</p></sec><sec id="S0003-S2003-S3001-S4002" disp-level="4"><label>3.3.1.2.</label><title>Docking into CDK-6/9</title><p>The multi-CDKIs <bold>1</bold>&#x02013;<bold>4</bold> exhibited potent anticancer activities against breast, ovarian, and colon cancers which could be attributed to their pan-CDKs inhibitory activities<xref rid="CIT0015" ref-type="bibr"><sup>15&#x02013;18</sup></xref><sup>,</sup><xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>. The ability of these compounds to inhibit multi-CDKs could be attributed to the shared pharmacophoric groups between the four compounds, <xref ref-type="fig" rid="F0001">Figure 1</xref>. In addition, high sequence similarities were confirmed between different members in the CDK family. CDK-6 and CDK-9 have sequence similarity of 44% and 32% with CDK-2, respectively<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. These similarities could also allow the CDK-2 inhibitors to target other members in the CDK family.</p><p>Based on these findings, compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> which were designed bearing the pharmacophoric features of the multi-CDKI <bold>3</bold> were docked into the active sites of CDK-6 (pdb: 2EUF)<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref> and CDK-9 (pdb: 3TNH)<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>. The aim of this study was to evaluate the ability of the three compounds to bind to and inhibit these two kinases. Selection of these three compounds was based on their high CDK-2 inhibitory activities, Table 4. In addition, the two CDKs 6/9 were selected based on the results of the cell cycle analysis which revealed G<sub>1</sub> to S cell-cycle arrest by the three compounds (<bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold>), <xref ref-type="fig" rid="F0008">Figure 8</xref>.</p><p>The docking procedures into CDK-6/9 were essentially the same as those applied in the docking study into CDK-2<sup>25</sup>. Validation of docking study into CDK-6 revealed superposition of the re-docked ligand, palbociclib over the co-crystallized ligand with RMSD of 0.61&#x02009;&#x000c5;, while the re-docked CAN508 into CDK-9 superposed the position of the native ligand with RMSD of 1.06&#x02009;&#x000c5; (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Supplementary data, Figures S151 and S152</ext-link>). The docking results were presented in Table 6.</p><p>The results of the docking study into CDK-6 revealed good fitting of the three compounds with binding free energy in the range of &#x02212;9.84 to &#x02212;10.52&#x02009;kcal/mol compared to &#x02212;11.54 for palbociclib. Among the three pyrrolizines, the 4-fluorophenyl urea <bold>19a</bold> displayed the highest affinity towards CDKs-6, while compound <bold>18b</bold> showed the lowest binding free energy, Table 6.</p><p>Investigation of the binding interaction of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> with CDK-6 revealed the formation of 1&#x02013;3 conventional hydrogen bonds compared to one conventional hydrogen bond for palbociclib. The three compounds also exhibited several types of hydrophobic interactions with amino acids into the active site of CDK-6, <xref ref-type="fig" rid="F0011">Figure 11</xref>.</p><fig id="F0011" orientation="portrait" position="float"><label>Figure 11.</label><caption><p>3D binding modes, hydrogen bonding (shown as green dotted lines), and electrostatic interactions (shown as orang dotted lines) of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> (shown as sticks) into CDK-6 (pdb: 2EUF) and CDK-9 (pdb: 3TNH): (A) compound <bold>18b</bold> into CDK-6; (B) compound <bold>19a</bold> into CDK-6; (C) compound <bold>20a</bold> into CDK-6; (D) compound <bold>18b</bold> into CDK-9; (E) compound <bold>19a</bold> into CDK-9; (F) compound <bold>20a</bold> into CDK-9, amino acid residues shown as lines coloured by element, hydrogen atoms were omitted for clarity.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1837124_F0011_C"/></fig><p>The tested compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> exhibited higher binding affinities (&#x00394;G<sub>b</sub> = &#x02212;9.81 to &#x02212;10.40&#x02009;kcal/mol) towards CDK-9 compared to the native ligand, CAN508 (&#x00394;G<sub>b</sub> = &#x02212;6.29&#x02009;kcal/mol). The high affinities of the new compounds could be attributed to their bulkier size compared to CAN508 which allow them to occupy larger volume of the active site in CDK-9.</p><p>Compound <bold>19a</bold> also showed the highest affinity towards CDK-9. Investigation of the binding interactions of compound <bold>18b</bold> into CDK-9 revealed one conventional hydrogen bond with Ile25, while compound <bold>19a</bold> showed three hydrogen conventional bonds Thr29, Lys48, and Ala153, <xref ref-type="fig" rid="F0011">Figure 11</xref>. The results of the docking study into CDKs-6/9 indicated that the three compounds (<bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold>) could have potential inhibitory activities against the two kinases.</p><p>In attempt to compare the binding affinities of the three compounds against the CDKs, fold selectivity was calculated, <xref rid="t0006" ref-type="table">Table 6</xref>. The three compounds displayed higher affinities towards CDK-6/9 than CDK-2 with fold selectivity in the range of <bold>2.06</bold>&#x02013;3.58. These results suggest that the three compounds could have better inhibitory activities against CDK-6/9 than CDK-2.</p><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Docking results of compounds, <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> into CDK-6 (pdb: 2EUF) and CDK-9 (pdb: 3TNH) in comparison to the native ligands, palbociclib (LQQ) and CAN508 (F18).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Ligand</th><th colspan="3" align="center">CDK-6<hr/></th><th colspan="3" align="center">CDK-9<hr/></th></tr><tr><th align="center"><italic toggle="yes">&#x00394;G<sub>b</sub></italic><sup>a</sup></th><th align="center"><italic toggle="yes">K<sub>i</sub></italic><sup>b</sup></th><th align="center"><italic toggle="yes">Fs</italic><sup>c</sup></th><th align="center"><italic toggle="yes">&#x00394;G<sub>b</sub></italic><sup>a</sup></th><th align="center"><italic toggle="yes">K<sub>i</sub></italic><sup>b</sup></th><th align="center"><italic toggle="yes">Fs</italic><sup>c</sup></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>18b</bold></td><td align="left">&#x02212;9.84</td><td align="left">61.08&#x02009;nM</td><td align="left">3.17</td><td align="left">&#x02212;9.81</td><td align="left">64.89&#x02009;nM</td><td align="char" char=".">2.98</td></tr><tr><td align="left"><bold>19a</bold></td><td align="left">&#x02212;10.52</td><td align="left">19.41&#x02009;nM</td><td align="left">2.54</td><td align="left">&#x02212;10.40</td><td align="left">23.93&#x02009;nM</td><td align="char" char=".">2.06</td></tr><tr><td align="left"><bold>20a</bold></td><td align="left">&#x02212;10.30</td><td align="left">28.30&#x02009;nM</td><td align="left">3.58</td><td align="left">&#x02212;9.99</td><td align="left">47.27&#x02009;nM</td><td align="char" char=".">2.14</td></tr><tr><td align="left"><bold>LQQ<italic toggle="yes"><sup>d</sup></italic></bold></td><td align="left">&#x02212;11.54</td><td align="left">3.48&#x02009;nM</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>F18<italic toggle="yes"><sup>e</sup></italic></bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02212;6.29</td><td align="left">24.67&#x02009;&#x003bc;M</td><td align="center">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="TF14"><p><sup>a</sup>Binding free energy (kcal/mol).</p></fn><fn id="TF15"><p><sup>b</sup>Inhibition constant.</p></fn><fn id="TF16"><p><sup>c</sup>Fold selectivity towards CDK-6/9, calculated by dividing the K<sub>i</sub> value against CDK-2 by the K<sub>i</sub> value against CDK-6/9.</p></fn><fn id="TF17"><p><sup>d</sup>LQQ, palbociclib/.</p></fn><fn id="TF18"><p><sup>e</sup>F18, CAN508.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="S0003-S2003-S3002" disp-level="3"><label>3.3.2.</label><title><italic>In silico</italic> ADME and drug-likeness studies</title><p>One of the major problems in drug discovery and development is the poor pharmacokinetic profile of a drug candidate<xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>. The success of a drug candidate to pass the clinical investigation depends mainly on its pharmacokinetic as well as pharmacodynamic profile. Accordingly, the <italic>in silico</italic> studies of the physicochemical properties related to the pharmacokinetics of drug candidates have attracted considerable attention in the last two decades<xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref>.</p><p>In the current study, the physicochemical properties related to the pharmacokinetic (PK) profiles of the new compounds <bold>16&#x02013;20a&#x02013;c</bold> were evaluated using SwissADME (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>)<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref>. The new compounds were also evaluated for their drug-likeness score using the online Molsoft tools (<ext-link ext-link-type="uri" xlink:href="http://www.molsoft.com/mprop/">http://www.molsoft.com/mprop/</ext-link>). To predict the oral activity, the new compounds were also evaluated for any violation from Lipinski&#x02019;s rule<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>. The calculated values of the new compounds were compared with those of the multi-CDKIs, flavopiridol, palbociclib, compounds <bold>3</bold> and <bold>10</bold>. The results of this study are presented in <xref rid="t0007" ref-type="table">Table 7</xref>.</p><table-wrap id="t0007" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Molecular properties related to PKs and DLS of the new compounds in comparison to compounds <bold>3</bold>, <bold>10</bold>, flavopiridol and palbociclib.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="7" align="center">Physicochemical properties<hr/></th><th rowspan="2" align="center">Lipinski&#x02019;s rule</th><th rowspan="2" align="center">%Abs <italic toggle="yes"><sup>a</sup></italic></th><th rowspan="2" align="center">BS</th><th rowspan="2" align="center">DLS <italic toggle="yes"><sup>b</sup></italic></th></tr><tr><th align="left">Comp.</th><th align="center">MW</th><th align="center">MV</th><th align="center">TPSA</th><th align="center">MlogP</th><th align="center">RBs</th><th align="center">HB<sub>A</sub></th><th align="center">HB<sub>D</sub></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>16a</bold></td><td align="left">393.48</td><td align="left">431.15</td><td align="left">73.39</td><td align="left">1.97</td><td align="left">11</td><td align="left">3</td><td align="left">3</td><td align="left">Yes</td><td align="left">83.68</td><td align="left">0.55</td><td align="left">0.24</td></tr><tr><td align="left"><bold>16b</bold></td><td align="left">407.51</td><td align="left">452.09</td><td align="left">73.39</td><td align="left">2.18</td><td align="left">11</td><td align="left">3</td><td align="left">3</td><td align="left">Yes</td><td align="left">83.68</td><td align="left">0.55</td><td align="left">0.35</td></tr><tr><td align="left"><bold>16c</bold></td><td align="left">427.93</td><td align="left">448.35</td><td align="left">73.39</td><td align="left">2.45</td><td align="left">11</td><td align="left">3</td><td align="left">3</td><td align="left">Yes</td><td align="left">83.68</td><td align="left">0.55</td><td align="left">0.84</td></tr><tr><td align="left"><bold>17a</bold></td><td align="left">415.44</td><td align="left">427.60</td><td align="left">79.50</td><td align="left">1.71</td><td align="left">8</td><td align="left">4</td><td align="left">3</td><td align="left">Yes</td><td align="left">81.57</td><td align="left">0.55</td><td align="left">0.45</td></tr><tr><td align="left"><bold>17b</bold></td><td align="left">429.47</td><td align="left">448.54</td><td align="left">79.50</td><td align="left">1.92</td><td align="left">8</td><td align="left">4</td><td align="left">3</td><td align="left">Yes</td><td align="left">81.57</td><td align="left">0.55</td><td align="left">0.48</td></tr><tr><td align="left"><bold>17c</bold></td><td align="left">449.89</td><td align="left">444.79</td><td align="left">79.50</td><td align="left">2.19</td><td align="left">8</td><td align="left">4</td><td align="left">3</td><td align="left">Yes</td><td align="left">81.57</td><td align="left">0.55</td><td align="left">1.01</td></tr><tr><td align="left"><bold>18a</bold></td><td align="left">403.41</td><td align="left">401.67</td><td align="left">71.96</td><td align="left">2.39</td><td align="left">7</td><td align="left">4</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.17</td><td align="left">0.55</td><td align="left">0.65</td></tr><tr><td align="left"><bold>18b</bold></td><td align="left">417.44</td><td align="left">422.61</td><td align="left">71.96</td><td align="left">2.61</td><td align="left">7</td><td align="left">4</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.17</td><td align="left">0.55</td><td align="left">0.71</td></tr><tr><td align="left"><bold>18c</bold></td><td align="left">437.85</td><td align="left">418.86</td><td align="left">71.96</td><td align="left">2.87</td><td align="left">7</td><td align="left">4</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.17</td><td align="left">0.55</td><td align="left">0.86</td></tr><tr><td align="left"><bold>19a</bold></td><td align="left">435.48</td><td align="left">446.29</td><td align="left">70.99</td><td align="left">2.68</td><td align="left">7</td><td align="left">3</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.51</td><td align="left">0.55</td><td align="left">0.14</td></tr><tr><td align="left"><bold>19b</bold></td><td align="left">449.50</td><td align="left">467.23</td><td align="left">70.99</td><td align="left">2.88</td><td align="left">7</td><td align="left">3</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.51</td><td align="left">0.55</td><td align="left">0.30</td></tr><tr><td align="left"><bold>19c</bold></td><td align="left">469.92</td><td align="left">463.49</td><td align="left">70.99</td><td align="left">3.15</td><td align="left">7</td><td align="left">3</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.51</td><td align="left">0.55</td><td align="left">0.71</td></tr><tr><td align="left"><bold>20a</bold></td><td align="left">451.54</td><td align="left">460.28</td><td align="left">57.51</td><td align="left">2.67</td><td align="left">7</td><td align="left">2</td><td align="left">3</td><td align="left">Yes</td><td align="left">89.16</td><td align="left">0.55</td><td align="left">0.11</td></tr><tr><td align="left"><bold>20b</bold></td><td align="left">465.57</td><td align="left">481.22</td><td align="left">57.51</td><td align="left">2.87</td><td align="left">7</td><td align="left">2</td><td align="left">3</td><td align="left">Yes</td><td align="left">89.16</td><td align="left">0.55</td><td align="left">0.28</td></tr><tr><td align="left"><bold>20c</bold></td><td align="left">485.99</td><td align="left">477.48</td><td align="left">57.51</td><td align="left">3.14</td><td align="left">7</td><td align="left">2</td><td align="left">3</td><td align="left">Yes</td><td align="left">89.16</td><td align="left">0.55</td><td align="left">0.69</td></tr><tr><td align="left"><bold>10</bold></td><td align="left">447.92</td><td align="left">469.04</td><td align="left">58.48</td><td align="left">2.92</td><td align="left">7</td><td align="left">2</td><td align="left">3</td><td align="left">Yes</td><td align="left">88.82</td><td align="left">0.55</td><td align="left">0.71</td></tr><tr><td align="left"><bold>3</bold></td><td align="left">360.29</td><td align="left">306.76</td><td align="left">70.18</td><td align="left">2.64</td><td align="left">6</td><td align="left">6</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.79</td><td align="left">0.55</td><td align="left">0.98</td></tr><tr><td align="left"><bold>Flavopiridol</bold></td><td align="left">401.8</td><td align="left">382.75</td><td align="left">71.93</td><td align="left">1.75</td><td align="left">2</td><td align="left">5</td><td align="left">3</td><td align="left">Yes</td><td align="left">84.18</td><td align="left">0.55</td><td align="left">1.48</td></tr><tr><td align="left"><bold>Palbociclib</bold></td><td align="left">447.53</td><td align="left">479.27</td><td align="left">84.30</td><td align="left">1.13</td><td align="left">5</td><td align="left">6</td><td align="left">2</td><td align="left">Yes</td><td align="left">79.92</td><td align="left">0.55</td><td align="left">0.62</td></tr></tbody></table><table-wrap-foot><fn id="TF19"><p>MW: molecular weight; MV: molecular volume (A<sup>3</sup>); TPSA: topological polar surface area (A<sup>2</sup>); MlogP: logP (Moriguchi etal.); RBs: number of rotatable bonds; HB<sub>A</sub>: number of hydrogen bond acceptors; HB<sub>D</sub>: number of hydrogen bond donors.</p></fn><fn id="TF20"><p><sup>a</sup>%Abs (% absorbed orally) = 109&#x02212;(0.345 &#x000d7; TPSA; BS: bioavailability score.</p></fn><fn id="TF21"><p><sup>b</sup>DLS: drug-likeness score; Lipinski&#x02019;s rule, yes mean no violation; MV, TPSA, and DLS were calculated using Molsoft (<ext-link ext-link-type="uri" xlink:href="http://www.molsoft.com/mprop/">http://www.molsoft.com/mprop/</ext-link>); other parameters calculated using SwissADME (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>).</p></fn></table-wrap-foot></table-wrap><p>The molecular weights of the new compounds were in the range 393.48&#x02013;485.99&#x02009;Da which was less than 500. Moreover, the calculated molecular volumes of the new compounds were in the range of 401.67&#x02009;&#x02212;&#x02009;481.22 A<sup>3</sup>, which was comparable to multi-CDKIs, flavopiridol and palbociclib. In addition, the new compounds showed topological polar surface areas (TPSA) in the range of 57.51&#x02013;79.50 A<sup>2</sup> compared to 71.93 and 84.30 A<sup>2</sup> for flavopiridol and palbociclib, respectively, <xref rid="t0007" ref-type="table">Table 7</xref>.</p><p>The Clog P (MlogP) values of the new compounds were in the range of 1.71&#x02013;3.15, which was higher than those of flavopiridol and palbociclib but was comparable with that compound <bold>3</bold>. Compounds <bold>19c</bold> and <bold>20c</bold> were the most lipophilic with ClogP values of 3.15 and 3.14, respectively. The chemical structure of the new compounds have 2&#x02013;4 hydrogen bond acceptors (HB<sub>A</sub> &#x0003c;10) and 3 hydrogen bond donors (HB<sub>D</sub> &#x0003c; 5). These results indicated that all the new compounds conform to Lipinski&#x02019;s rule. In addition, the new compounds showed drug-likeness score (DLS) in the range of 0.11&#x02013;1.01, compared to 0.62 for palbociclib, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Supplementary data (Table S2)</ext-link>. Among the new compounds, compound <bold>17c</bold> displayed the highest DLS.</p><p>The expected GIT absorption percent (%Abs) of the new compounds was also calculated according to the previous report<xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref>. The new compounds exhibited %Abs in the range of 81.57&#x02013;89.16% compared to 84.79&#x02013;84.18% for flavopiridol.</p><p>The study also revealed that compounds <bold>17a</bold>,<bold>b</bold>, <bold>18a</bold>,<bold>b</bold>, <bold>19a</bold>, and <bold>20a</bold>,<bold>b</bold> are expected to be substrates for P-glycoprotein and predicted to be effluated from the CNS by P-glycoprotein, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1837124">Supplementary data (Table S3)</ext-link>.</p></sec></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusions</title><p>In the current study, a library of 1302 pyrrolizine derivatives was designed based on the pyrrolizine-5-carboxamide scaffold <bold>10</bold>. The 3D pharmacophore model of the multi-CDKI <bold>3</bold> was used in the virtual screening of this library. The top-scoring hits were synthesised and evaluated for their cytotoxic activities against three cancer (MCF-7, A2780, and HT29) cell lines. The results revealed cytotoxic activities against the three cancer cell lines with IC<sub>50</sub> values in the range of 0.16&#x02013;34.13&#x02009;&#x003bc;M. Among the new derivatives, compound <bold>18b</bold> was the most active against MCF-7 cells (IC<sub>50</sub> = 0.19&#x02009;&#x003bc;M). In addition, compounds <bold>19a</bold> and <bold>20a</bold> were the most potent in inhibiting the growth of and HT29 and A2780 cell lines, respectively. The results of the MTT assay of the new compounds against normal MRC-5 cells also revealed IC<sub>50</sub> values in the range of 0.10&#x02013;11.86&#x02009;&#x000b5;M. Compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> increased the apoptotic events and arrested MCF-7 cells at the G<sub>1</sub> phase. Mechanistic study of compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> revealed potent <italic>in&#x000a0;vitro</italic> inhibition in CDK-2 activity (IC<sub>50</sub> = 25.53&#x02013;115.3&#x02009;nM). Among the three derivatives, compound <bold>19a</bold> exhibited the highest inhibitory activity against CDK-2. <italic>In silico</italic> ADME study revealed that all new compounds conform to Lipinski&#x02019;s rule. In addition, the molecular docking analyses indicated that compounds <bold>18b</bold>, <bold>19a</bold>, and <bold>20a</bold> fit snugly into the active sites of CDK-2/6/9. Among the three derivatives, compound <bold>19a</bold> also displayed the highest binding scores and exhibited several hydrogen bonding interactions with the three kinases. These preliminary results suggested that compound <bold>19a</bold> could serve as a promising scaffold in the discovery and development of new potent anticancer agents.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM9339"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1837124_SM9339.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>NS.</given-names></name></person-group>
<article-title>Kinase inhibitors: the road ahead</article-title>. <source>Nat Rev Drug Discov</source>
<year>2018</year>;<volume>17</volume>:<fpage>353</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">29545548</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhullar</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Lagaron</surname><given-names>NO</given-names></name>, <name name-style="western"><surname>McGowan</surname><given-names>EM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Kinase-targeted cancer therapies: progress, challenges and future directions</article-title>. <source>Mol Cancer</source>
<year>2018</year>;<volume>17</volume>:<fpage>48</fpage>.<pub-id pub-id-type="pmid">29455673</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Clausen</surname><given-names>MH.</given-names></name></person-group>
<article-title>FDA-approved small-molecule kinase inhibitors</article-title>. <source>Trends Pharmacol Sci</source>
<year>2015</year>;<volume>36</volume>:<fpage>422</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">25975227</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roskoski</surname><given-names>R</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update</article-title>. <source>Pharmacol Res</source>
<year>2020</year>;<volume>152</volume>:<fpage>104609</fpage>.<pub-id pub-id-type="pmid">31862477</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Doroshow</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Kummar</surname><given-names>S.</given-names></name></person-group>
<article-title>United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies</article-title>. <source>Curr Probl Cancer</source>
<year>2013</year>;<volume>37</volume>:<fpage>110</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">23972982</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadesse</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Caldon</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Tilley</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group>
<article-title>Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update</article-title>. <source>J Med Chem</source>
<year>2019</year>;<volume>62</volume>:<fpage>4233</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">30543440</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Faha</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The cdk2 kinase is required for the G1-to-S transition in mammalian cells</article-title>. <source>Oncogene</source>
<year>1993</year>;<volume>8</volume>:<fpage>1593</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">8502482</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keyomarsi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pardee</surname><given-names>AB.</given-names></name></person-group>
<article-title>Redundant cyclin overexpression and gene amplification in breast cancer cells</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>1993</year>;<volume>90</volume>:<fpage>1112</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">8430082</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression</article-title>. <source>Oncotarget</source>
<year>2015</year>;<volume>6</volume>:<fpage>20801</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26204491</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Monden</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miyoshi</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells</article-title>. <source>Int J Oncol</source>
<year>1998</year>;<volume>13</volume>:<fpage>233</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9664116</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma</article-title>. <source>Transl Oncol</source>
<year>2016</year>;<volume>9</volume>:<fpage>548</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">27863310</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faber</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Chiles</surname><given-names>TC.</given-names></name></person-group>
<article-title>Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas</article-title>. <source>Cell Cycle</source>
<year>2007</year>;<volume>6</volume>:<fpage>2982</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18156799</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of CDK2 as a novel target in treatment of prostate cancer</article-title>. <source>Future Oncol</source>
<year>2018</year>;<volume>14</volume>:<fpage>709</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">29323532</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>ZP</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Ratner</surname><given-names>ES.</given-names></name></person-group>
<article-title>Targeting cyclin-dependent kinases for treatment of gynecologic cancers</article-title>. <source>Front Oncol</source>
<year>2018</year>;<volume>8</volume>:<fpage>303</fpage>.<pub-id pub-id-type="pmid">30135856</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdouchi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Keyser</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines</article-title>. <source>Mol Cancer Ther</source>
<year>2004</year>;<volume>3</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">14749470</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyatt</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Woodhead</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Berdini</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</article-title>. <source>J Med Chem</source>
<year>2008</year>;<volume>51</volume>:<fpage>4986</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">18656911</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seftel</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Kuruvilla</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kouroukis</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group</article-title>. <source>Leuk Lymphoma</source>
<year>2017</year>;<volume>58</volume>:<fpage>1358</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">27750483</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yun</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ullah</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name></person-group>
<article-title>Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in&#x000a0;vitro and in&#x000a0;vivo anticancer activity</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>189</volume>:<fpage>112073</fpage>.<pub-id pub-id-type="pmid">31991336</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honma</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Aoyama</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design</article-title>. <source>J Med Chem</source>
<year>2001</year>;<volume>44</volume>:<fpage>4615</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">11741479</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yakowec</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery and evaluation of dual CDK1 and CDK2 inhibitors</article-title>. <source>Cancer Res</source>
<year>2006</year>;<volume>66</volume>:<fpage>4299</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">16618755</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wr&#x000f3;bel</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Kie&#x00142;bus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kaczor</surname><given-names>AA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of nitroaryl urea derivatives with antiproliferative properties</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>608</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">26114307</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>M&#x000f6;bitz</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Drueckes</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Type II inhibitors targeting CDK2</article-title>. <source>ACS Chem Biol</source>
<year>2015</year>;<volume>10</volume>:<fpage>2116</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">26158339</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abdelazeem</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Arafa</surname><given-names>e-SA</given-names></name>, <name name-style="western"><surname>Abdellatif</surname><given-names>KR.</given-names></name></person-group>
<article-title>Design, synthesis and pharmacological evaluation of novel pyrrolizine derivatives as potential anticancer agents</article-title>. <source>Bioorg Chem</source>
<year>2014</year>;<volume>53</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24462996</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abdelazeem</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Omar</surname><given-names>HA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pyrrolizines: design, synthesis, anticancer evaluation and investigation of the potential mechanism of action</article-title>. <source>Bioorg Med Chem</source>
<year>2017</year>;<volume>25</volume>:<fpage>5637</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">28916158</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shawky</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abourehab</surname><given-names>MAS</given-names></name>, <name name-style="western"><surname>Abdalla</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Gouda</surname><given-names>AM.</given-names></name></person-group>
<article-title>Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: design, synthesis and investigation of cytotoxicity and anti-inflammatory potency</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>185</volume>:<fpage>111780</fpage>.<pub-id pub-id-type="pmid">31655429</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>164</volume>:<fpage>615</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">30639897</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tutone</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Almerico</surname><given-names>AM.</given-names></name></person-group>
<article-title>Recent advances on CDK inhibitors: an insight by means of in silico methods</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>142</volume>:<fpage>300</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">28802482</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ece</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sevin</surname><given-names>F.</given-names></name></person-group>
<article-title>The discovery of potential cyclin A/CDK2 inhibitors: a combination of 3D QSAR pharmacophore modeling, virtual screening, and molecular docking studies</article-title>. <source>Med Chem Res</source>
<year>2013</year>;<volume>22</volume>:<fpage>5832</fpage>&#x02013;<lpage>43</lpage>.</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammad</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Batra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dahiya</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of high-affinity inhibitors of cyclin-dependent kinase 2</article-title>
<source>towards anticancer therapy. Molecules</source>
<year>2019</year>;<volume>24</volume>:<fpage>4589</fpage>.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakanishi</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Murata</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nagata</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>96</volume>:<fpage>396</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">25912672</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Muegge</surname><given-names>I.</given-names></name></person-group>
<article-title>Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>1536</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">16509572</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>J-W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M-Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>235</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">31760818</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulsen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>William</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Blanchard</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</article-title>. <source>J Mol Model</source>
<year>2013</year>;<volume>19</volume>:<fpage>119</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">22820730</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>D.</given-names></name></person-group>
<article-title>Pharmacophore-based virtual screening</article-title>. <source>Methods Mol Biol</source>
<year>2011</year>;<volume>672</volume>:<fpage>261</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">20838973</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2015</year>;<volume>25</volume>:<fpage>4069</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">26316466</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sunseri</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koes</surname><given-names>DR.</given-names></name></person-group>
<article-title>Pharmit: interactive exploration of chemical space</article-title>. <source>Nucleic Acids Res</source>
<year>2016</year>;<volume>44</volume>:<fpage>W442</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27095195</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Almalki</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Azim</surname><given-names>MA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, and biological evaluation of some novel pyrrolizine derivatives as COX inhibitors with anti-inflammatory/analgesic activities and low ulcerogenic liability</article-title>. <source>Molecules</source>
<year>2016</year>;<volume>21</volume>:<fpage>201</fpage>.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attalah</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Abdalla</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Aslam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ethyl benzoate bearing pyrrolizine/indolizine moieties: design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>94</volume>:<fpage>103371</fpage>.<pub-id pub-id-type="pmid">31708230</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abdelazeem</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Abdalla</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>M.</given-names></name></person-group>
<article-title>Pyrrolizine-5-carboxamides: exploring the impact of various substituents on anti-inflammatory and anticancer activities</article-title>. <source>Acta Pharm</source>
<year>2018</year>;<volume>68</volume>:<fpage>251</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">31259695</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Abdel Gawad</surname><given-names>NM.</given-names></name></person-group>
<article-title>Synthesis of novel indolizine, diazepinoindolizine and pyrimidoindolizine derivatives as potent and selective anticancer agents</article-title>. <source>Res Chem Intermed</source>
<year>2015</year>;<volume>41</volume>:<fpage>9687</fpage>&#x02013;<lpage>701</lpage>.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsaady</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Edrees</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Gawad</surname><given-names>NMA.</given-names></name></person-group>
<article-title>Synthesis and biological evaluation of some novel Schiff base derivatives as potential anticancer agents</article-title>. <source>J Chem Pharm Res</source>
<year>2016</year>;<volume>8</volume>:<fpage>273</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malki</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>HEA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>152</volume>:<fpage>31</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">29684708</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkahtani</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Alanazi</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Aleanizy</surname><given-names>FS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: molecular docking studies</article-title>. <source>Saudi Pharm J</source>
<year>2019</year>;<volume>27</volume>:<fpage>682</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">31297023</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdalla</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Shaheen</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Abdallah</surname><given-names>QMA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Proapoptotic activity of Achillea membranacea essential oil and its major constituent 1,8-cineole against A2780 ovarian cancer cells</article-title>. <source>Molecules</source>
<year>2020</year>;<volume>25</volume>:<fpage>1582</fpage>.</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells</article-title>. <source>Bioorg Med Chem</source>
<year>2018</year>;<volume>26</volume>:<fpage>3491</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">29853338</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Huey</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lindstrom</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title>. <source>J Comput Chem</source>
<year>2009</year>;<volume>30</volume>:<fpage>2785</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">19399780</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Almalki</surname><given-names>FA.</given-names></name></person-group>
<article-title>Carprofen: a theoretical mechanistic study to investigate the impact of hydrophobic interactions of alkyl groups on modulation of COX-1/2 binding selectivity</article-title>. <source>SN Appl Sci</source>
<year>2019</year>;<volume>1</volume>:<fpage>332</fpage>.</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almalki</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Bin Ali</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Almehmadi</surname><given-names>OM.</given-names></name></person-group>
<article-title>Profens: a comparative molecular docking study into cyclooxygenase-1/2</article-title>. <source>Drug Invent Today</source>
<year>2019</year>;<volume>11</volume>:<fpage>480</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attallah</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Gouda</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>IT</given-names></name>, <name name-style="western"><surname>Abouzeid</surname><given-names>L.</given-names></name></person-group>
<article-title>Design, synthesis, 99mTc labeling, and biological evaluation of a novel pyrrolizine derivative as potential anti-inflammatory agent</article-title>. <source>Radiochemistry</source>
<year>2017</year>;<volume>59</volume>:<fpage>630</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Dassault Systems BIOVIA,</collab></person-group>
<source>Discovery studio visualizer</source>, v16.1.0.15350. <publisher-loc>San Diego (CA)</publisher-loc>: <publisher-name>Dassault Systems</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schulze-Gahmen</surname><given-names>U.</given-names></name></person-group>
<article-title>Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>3826</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">16789739</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hole</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Noble</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Endicott</surname><given-names>JA.</given-names></name></person-group>
<article-title>The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508</article-title>. <source>ACS Chem Biol</source>
<year>2012</year>;<volume>7</volume>:<fpage>811</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22292676</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daina</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Michielin</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name></person-group>
<article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source>Sci Rep</source>
<year>2017</year>;<volume>7</volume>:<fpage>42717</fpage>.<pub-id pub-id-type="pmid">28256516</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Lombardo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dominy</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Feeney</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>. <source>Adv Drug Deliv Rev</source>
<year>1997</year>;<volume>23</volume>:<fpage>3</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Abraham</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Le</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Rate-limited steps of human oral absorption and QSAR studies</article-title>. <source>Pharm Res</source>
<year>2002</year>;<volume>19</volume>:<fpage>1446</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">12425461</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkins</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Gershell</surname><given-names>LJ.</given-names></name></person-group>
<article-title>Selective anticancer drugs</article-title>. <source>Nat Rev Drug Discov</source>
<year>2002</year>;<volume>1</volume>:<fpage>491</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">12120255</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asghar</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Witkiewicz</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Knudsen</surname><given-names>ES.</given-names></name></person-group>
<article-title>The history and future of targeting cyclin-dependent kinases in cancer therapy</article-title>. <source>Nat Rev Drug Discov</source>
<year>2015</year>;<volume>14</volume>:<fpage>130</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25633797</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Urb&#x000e1;n</surname><given-names>L.</given-names></name></person-group>
<article-title>The impact of early ADME profiling on drug discovery and development strategy</article-title>. <source>DDW Drug Discov World</source>
<year>2004</year>;<volume>5</volume>:<fpage>73</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>AP.</given-names></name></person-group>
<article-title>Screening for human ADME/Tox drug properties in drug discovery</article-title>. <source>Drug Discov Today</source>
<year>2001</year>;<volume>6</volume>:<fpage>357</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">11267922</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hannongbua</surname><given-names>S.</given-names></name></person-group>
<article-title>In-silico ADME models: a general assessment of their utility in drug discovery applications</article-title>. <source>Curr Top Med Chem</source>
<year>2011</year>;<volume>11</volume>:<fpage>358</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">21320065</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>In-silico ADME studies for new drug discovery: from chemical compounds to Chinese herbal medicines</article-title>. <source>Curr Drug Metab</source>
<year>2017</year>;<volume>18</volume>:<fpage>535</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28302029</pub-id></mixed-citation></ref></ref-list></back></article>